UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 1 of 53STATISTICAL ANALYSIS PLAN 
Study: SP0966
Product: Lacosamide
A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE 
SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS 
≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH 
GENERALIZED SEIZURES
SAP/Amendment Number Date
Final SAP 28 Apr 2015
Amendment 1, Post Dry-run 06 March 2018
Confidentiality Statement
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, reproduced, 
published, or otherwise used without the express permission of UCB.REDACTED r 20152015
archarchCOPY 
This document ThThcannot anbe used to support any marketing20120188authorization application VEVE
OMES MES
ESESandTO ITO I
E THETany ININextensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 2 of 53TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................5
1 INTRODUCTION .............................................................................................................72 PROTOCOL SUMMARY.................................................................................................72.1 Study objectives ............................................................................................................ .....7
2.2 Study variables............................................................................................................. ......7
2.2.1 Safety variables......................................................................................................7
2.2.1.1 Primary safety variables ..............................................................................72.2.1.2 Secondary safety variables ..........................................................................72.2.1.3 Other variables assessing safety..................................................................82.2.1.4 Exploratory Safety variables .......................................................................8
2.2.2 Efficacy variables ..................................................................................................8
2.2.2.1 Preliminary efficacy variables.....................................................................82.2.2.2 Exploratory eff icacy variables.....................................................................9
2.2.3 Pharmacokinetic and pharmacodynamic variables..............................................10
2.3 Study design and conduct ................................................................................................102.4 Determination of sample size...........................................................................................103 DATA ANALYSIS CONSIDERATIONS ......................................................................113.1 General presentation of summaries and analyses ............................................................113.2 General study level definitions ........................................................................................11
3.2.1 Last dose of LCM ................................................................................................113.2.2 Relative day .........................................................................................................113.2.3 Study periods .......................................................................................................123.2.4 Last Visit..............................................................................................................123.2.5 Age and age groups .............................................................................................12
3.3 Definition of Baseline values...........................................................................................133.4 Protocol deviations......................................................................................................... ..13
3.5 Analysis sets............................................................................................................... ......13
3.5.1 Safety Set .............................................................................................................133.5.2 Full Analysis Set..................................................................................................143.5.3 Pharmacokinetic Per Protocol Set .......................................................................14
3.6 Treatment assignment and treatment groups ...................................................................143.7 Center pooling strategy....................................................................................................1 4
3.8 Coding dictionaries ......................................................................................................... .14
3.9 Changes to protocol-defined analyses..............................................................................144 STATISTICAL/ANALYTICAL ISSUES .......................................................................144.1 Adjustments for covariates...............................................................................................144.2 Handling of dropouts or missing data..............................................................................14SS.....
d anald anal
..........
............COPY .....
............
This document 3.73.7
33cannot 3
TreTrebeFuFuused s......
afetyafetyto osupportroupoup
ine vane v
ons....ns...any .........
upspsmarketing .........
..........
............authorization ....
..........
lyysesses
..........application ........
...........
............
.....and ..........any ...........extensions ...............
..........
..........or.........variations ...7..7thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 3 of 534.2.1 Visit mapping in case of premature discontinuation ...........................................14
4.2.2 Missing data.........................................................................................................144.2.3 Incomplete or missing dates for adverse events and concomitant medication....154.2.4 Incomplete dates for the last administration of LCM..........................................16
4.3 Interim analyses and data monitoring ..............................................................................164.4 Multicenter studies......................................................................................................... ..16
4.5 Multiple comparisons/multiplicity...................................................................................174.6 Use of an efficacy subset of subjects ...............................................................................174.7 Active-control studies intended to show equivalence......................................................174.8 Examination of subgroups ...............................................................................................175 STUDY POPULATION CHARACTERISTICS.............................................................175.1 Subject disposition......................................................................................................... ..17
5.2 Protocol deviations......................................................................................................... ..18
6 DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................186.1 Demographics ................................................................................................................ ..18
6.2 Other Baseline characteristics..........................................................................................186.3 Medical history and concomitant diseases.......................................................................206.4 Prior and concomitant medications..................................................................................207 MEASUREMENTS OF TREATMENT COMPLIANCE...............................................217.1 Derivation of compliance.................................................................................................217.2 Presentation of compliance ..............................................................................................218 SAFETY ANALYSES.....................................................................................................218.1 Primary safety variables...................................................................................................2 1
8.1.1 Generalized spike-wave discharges.....................................................................218.1.2 Generalized seizures ............................................................................................22
8.2 Secondary safety variables...............................................................................................22
8.2.1 3Hz spike-wave discharges..................................................................................228.2.2 Adverse events.....................................................................................................22
8.3 Exploratory safety variables.............................................................................................238.4 Extent of exposure .......................................................................................................... .23
8.5 Clinical laboratory evaluations ........................................................................................248.6 Vital signs, physical findings, and other observations related to safety ..........................25
8.6.1 Vital signs, body weight, height, BMI, and head circumference ........................258.6.2 Electrocardiograms ..............................................................................................268.6.3 Physical and neurological examination ...............................................................278.6.4 Tanner stage assessment ......................................................................................288.6.5 Achenbach Child Behavior Checklist..................................................................288.6.6 BRIEF-P and BRIEF assessment.........................................................................29
REDACTED T COMT COM
...........
..................COPY .........
.............
This document8.68.cannotinicanica
VitaVita
66bet of t of 
llused rr
oryrysafsaf
extose ese esupport z
ariablesriable
e--wavwavany wavwa
uresuresmarketing ...
............
.............
ave dave authorization................
MPLIMPLI
...........
.............application R
............
............
...........and .......
ISSTITIany .........
...extensions...........
..............
................or ......variations 177
171thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 4 of 539 ANALYSES OF EFFICACY VARIABLES...................................................................31
9.1 Preliminary Efficacy  Variables........................................................................................31
9.1.1 Seizure days .........................................................................................................319.1.2 Clinical global impression of change...................................................................319.1.3 Caregiver’s global impression of change ............................................................329.1.4 Pediatric quality of life inventory........................................................................329.1.5 Health care resource use ......................................................................................33
9.2 Exploratory  Efficacy Variables.......................................................................................3310 PHARMACOKINETICS.................................................................................................3410.1 Descriptive statistics of LCM and AED plasma concentrations......................................3410.2 Population pharmacokinetics and exposure response......................................................3411 OTHER ANALYSES ......................................................................................................3412 REFERENCES ................................................................................................................3513 APPENDICES .................................................................................................................3613.1 Significant Adverse Events..............................................................................................3613.2 Marked abnormality criteria for laboratory data..............................................................37
13.2.1 Marked abnormality criteria for hematology data ...............................................3713.2.2 Marked abnormality criteria for chemistry data ..................................................38
14 AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN (SAP) ......................4214.1 Amendment 1................................................................................................................ ...42
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE.....................................................53
LIST OF TABLES
Table 8‒1: Vital Signs Abnormality Criteria.....................................................................25
Table 8‒2: Electrocardiogram Abnormality Criteria .........................................................26
Table 8‒1: CBCL/1½-5......................................................................................................28
Table 8‒2: CBCL/6-18.......................................................................................................29
Table 8‒3: BRIEF-P questionnaire scoring .......................................................................29
Table 8‒4: BRIEF questionnaire scoring...........................................................................30
Table 13-1: List of other significant AEs............................................................................36
Table 13‒2: Hematology abnormality criteria .....................................................................37
Table 13‒3: Chemistry abnormality criteria ........................................................................38REDACTED em
IICALCAL
...........
SIGNAIGNACOPY tologytology
mistrmistr
This documentTablabl
TTcannot 4:4:
e1313be used BCC
BRBRto CLCL//supportrdiogradiogr
/1½1½-5-5anynormnormmarketing A
LISLIauthorizationy
ryrydatdat
L ANAANA
...........
ATTURURapplication .
............
............
datadataand .......
......any .........
...extensions ...........
.........
................or ......variations 333
333thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 5 of 53LIST OF ABBREVIATIONS
AE adverse event
AED antiepileptic drug 
Bayley-III Bayley Scales of Infant and Toddler Development®, 
Third Edition
BMI body mass index
BP blood pressure 
BRIEF® Behavior Rating Inventory of Executive Function®
BRIEF®-P Behavior Rating Inventory of Executive Function®-
Preschool Version
CBCL Child Behavior Checklist
CV coefficient of variation
DEM Data Evaluation Meeting
DMC Data Monitoring CommitteeECG electrocardiogram
eCRF electronic Case Report form
EEG electroencephalogram
ER emergency room
ET Early TerminationFAS Full Analysis Set
FSH follicle stimulating hormone
GEC Global Executive Composite
ILAE International League Against Epilepsy
LCM lacosamide
LH luteinizing hormone
MedDRA® Medical Dictionary for Regulatory ActivitiesPedsQL Pediatric Quality of Life Inventory
PK pharmacokinetic
PT preferred term
PK-PPS Pharmacokinetic Per Protocol Set
SAP Statistical Analysis PlanSD standard deviation
SOC system organ class
SPD Specification of Protocol Deviations
SS Safety SetREDACTEDhaloghalo
cy rooy roo
y Termy Term
ll Anll AnCOPY eport feport
gragra
This document KK--PP
SASAcannot PPPPbe used to support any IImarketingnalysisnalysi
llicle stlicle s
GlobGloauthorization for
amm
mm
minatioinatioapplication rmmand any extensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 6 of 53T3 triiodothyronine
T4 thyroxine
TEAE treatment-emergent adverse event
TEMA treatment-emergent markedly abnormal
TSH thyroid stimulating hormone
WHO-DD World Health Organization Drug Dictionary
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 7 of 531 INTRODUCTION
This Statistical Analysis Plan (SAP) defines the scope of statistical analyses and provides a 
detailed description of statistical methodology for the statistical analyses to support the final 
clinical study report for SP0966.
2 PROTOCOL SUMMARY
Protocol Date: 30 May 2012
Amendment 1: 19 Oct 2012Amendment 2: 09 Nov 2012
Amendment 3: 21 Jun 2013
Amendment 4: 25 Feb 2014Amendment 5: 26 Feb 2015
2.1 Study objectives
The objectives of this study are:
!To evaluate the safety and tolerability of lacosamide (LCM) when added to 1 to 3 
concomitant antiepileptic drugs (AEDs) in pediatric subjects with epilepsy syndromes associated with generalized seizures
!To obtain preliminary efficacy data of LCM on seizure frequency in pediatric epilepsy 
syndromes associated with generalized seizures
!An additional objective is to evaluate the pharmacokinetic (PK) of LCM in subjects ≥1 
month to <18 years of age.
2.2 Study variables
2.2.1 Safety variables
2.2.1.1 Primary safety variablesThe primary variables assessing safety are:
!Changes in count of generalized spike-wave discharges on 24-hour ambulatory 
electroencephalogram (EEG) from Visit 2 to Visit 6 
!Change in days with any generalized seizures (absence, myoclonic, clonic, tonic, tonic 
clonic, atonic, partial evolving to secondarily generalized) per 28 days from the Baseline 
Period to the Maintenance Period 
The assessment of seizure days will be based on the seizure diary.
2.2.1.2 Secondary safety variables
The secondary variables assessing safety are:
!Changes in count of 3Hz spike-wave discharges (during waking hours) on 24-hour 
ambulatory EEG from Visit 2 to Visit 6 REDACTED CM oCM o
ed seized seiz
luate tluate tCOPYdede
atric satric 
This documentThe he 
2.22.2cannonic, ac, a
eriod riod 
asasbee in de in 
atoatousedu
phalophalo
dadtont ont osupportafetyafet
assessasses
fany eess
tytymarketing the heauthorization n sen seiziz
zureszures
ephphapplication CM)M)w
ubjectubjecand any extensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 8 of 53!Adverse events (AEs) as reported spontaneously by the subject and/or caregiver, or observed 
by the investigator
!Subject withdrawals due to AEs
2.2.1.3 Other variables assessing safety
The other safety variables are:
!Changes in hematology, clinical chemistry, and urinalysis parameters
!Changes in hormone status (follicle stimulating hormone [FSH], luteinizing hormone [LH], 
triiodothyronine [T3], thyroxine [T4], thyroid stimulating hormone [TSH], and testosterone, 
as appropriate)
!Changes in 12-lead electrocardiograms (ECGs)
!Changes in vital sign measurements (ie, blood pressure [BP] and pulse rate)
!Physical and neurological examination findings
!Changes in body weight, height, and calculated body mass index (BMI)
!Changes in Tanner Stage (if applicable)
!Behavioral assessment (Achenbach Child Behavior Checklist [CBCL/1½-5 or CBCL/6-18]) 
for pediatric subjects ≥18 months of age
2.2.1.4 Exploratory Safety variables
!Decrease in generalized spike-wave discharges on 24-hour ambulatory EEG by syndrome 
subgroups
2.2.2 Efficacy variables
2.2.2.1 Preliminary efficacy variablesVariables used to assess preliminary efficacy will include:
!Change in days with absence seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Change in days with myoclonic seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Change in days with clonic seizures per 28 days from the Baseline Period to the Maintenance 
Period 
!Change in days with tonic seizures per 28 days from the Baseline Period to the Maintenance 
Period
!Change in days with tonic-clonic seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Change in days with atonic seizures per 28 days from the Baseline Period to the Maintenance 
PeriodREDACTED blesbles
dischdischCOPY avioravior CC
This documentPP
!!cannot od d 
ChangChan
PerPebee in de in usedy
e PerPer
dadatowitwisupportbsencsen
d
thhanyminarminarmarketing cacyacyvyyauthorization hargesargesapplicationdex (dex 
Checklheckand (B(Banyrateratextensionsstosstos
e))ore [Le [L
stestevariations LLHHthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 9 of 53!Change in days with partial evolving to secondarily generalized seizures per 28 days from the 
Baseline Period to the Maintenance Period
!Percent change in days with any generalized seizures (absence, myoclonic, clonic, tonic, 
tonic-clonic, atonic, partial evolving to secondarily generalized) per 28 days from the 
Baseline Period to the Maintenance Period
!Percent change in days with absence seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Percent change in days with myoclonic seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Percent change in days with clonic seizures per 28 days from the Baseline Period to the 
Maintenance Period 
!Percent change in days with tonic seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Percent change in days with tonic-clonic seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Percent change in days with atonic seizures per 28 days from the Baseline Period to the 
Maintenance Period
!Percent change in days with partial evolving to secondarily generalized seizures per 28 days 
from the Baseline Period to the Maintenance Period
!Changes in count of generalized spike-wave discharges on 24-hour ambulatory EEG from 
Visit 2 to Visit 9 or at Early Termination (ET)
!Changes in count of 3Hz spike-wave discharges (during waking hours) on 24-hour 
ambulatory EEG from Visit 2 to Visit 9 or at ET
!Clinical Global Impression of Change upon completion of the Maintenance Period 
(Termination) or at ET
!Caregiver’s Global Impression of Change upon completion of the Maintenance Period 
(Termination) or at ET
!Change in quality of life assessment (Pediatric Quality of Life Inventory [PedsQL™]) for 
subjects ≥1 month to ≤18 years of age
2.2.2.2 Exploratory efficacy variables
!At least 50 percent reduction in generalized seizures per 28 days by study period (titration 
and maintenance period) and syndrome subgroup
!Increase in generalized seizures of more than 25 percent per 28 days during the study period 
by syndrome subgroup
!Percent change in days with any generalized seizures per 28 days during the study period by 
syndrome subgroupREDACTEDng tong t
nance nance 
ike-wike-w
minatiminatiCOPY8 da8 d
to sto
This documentaa
!!cannot At leaAt lea
andandbe ≥usedqualitualit
1 m1 mto r atasupport l ImpreImpr
attETEanyn of Cn of Cmarketing ionon(
wave disave d
to Visio Vis
Chauthorization seconecon
PerioPerio
wave dave d
(E(Eapplication fromro
s from fromand om tmtanyine Pne Pextensions riod tiod t
Pord tod tvariations ototthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 10 of 532.2.3 Pharmacokinetic and pharmacodynamic variables
Plasma concentrations of LCM and concomitant AEDs will be obtained in order to: 
!Develop a population PK model of LCM
!Investigate the effect of LCM on the steady-state plasma concentrations of concomitant 
AEDs
!Investigate the correlation between LCM plasma concentrations and efficacy or safety
2.3 Study design and conduct
SP0966 is a Phase 2, multicenter, open-label exploratory study designed to assess the safety and 
preliminary efficacy of oral LCM as adjunctive therapy for epilepsy syndromes associated with generalized seizures in pediatric subjects ≥1 month to <18 years of age. 
The study treatment is LCM in either the oral solution formulation or tablet formulation. The 
formulation of LCM to be administered is based on the weight of the subject. 
Subjects will not be randomized, but all subjects who sign the informed consent form at Visit 1 
will be assigned a unique identification number. 
Approximately 50 subjects will be enrolled at approximately 50 sites in Europe, and North 
America, and other regions as deemed necessary. It is planned to enroll approximately 
40 subjects between 4 years and <18 years of age and at least 10 subjects between 1 month and 
<4 years of age.
The study will begin with subject screening at Visit 1 and will consist of a 6-week prospective 
Baseline Period. If all inclusion criteria are met and no exclusion criterion is met, the subject will 
begin a 6-week Titration Period (LCM dosing flexibility allowed based on tolerability) starting at Visit 2. Subjects will initiate treatment with LCM oral solution at 2mg/kg/day, or LCM tablets at 
100mg/day based on body weight. The dose will be titrated to a level to optimize tolerability and 
seizure control, not to exceed 12mg/kg/day (oral solution) for subjects weighing <50kg, or 600mg/day (tablets/oral solution) in subjects weighing ≥50kg. Subjects will increase the LCM 
dose in a stepwise fashion on a weekly basis to optimize tolerability and seizure control.
At the end of the Titration Period (Visit 6), a 12-week Maintenance Period will begin. The LCM 
dose will remain stable throughout the Maintenance Period. Subjects who require a change in 
dose during the Maintenance Period will be withdrawn from the study. 
The end of the Maintenance Period will be Visit 9, or, if subjects withdraw early, the ET Visit. 
Subjects may be eligible for participation in the additional open-label study (SP848). Subjects 
who choose not to participate in the open-label study or subjects who discontinue due to other 
reasons will enter a 2- to 4-week Taper Period followed by a Safety Follow-Up Visit 2 weeks (±2 days) after the final dose of LCM and a Safety Follow-Up Telephone Contact 30 days 
(-1/+3 days) after the final dose of LCM. 
A Data Monitoring Committee (DMC) will oversee the safety of the study.
2.4 Determination of sample size
A total of 50 evaluable subjects are planned for enrollment for this study across 2 age groups. 
The first age group will consist of approximately 40 subjects between 4 years and <18 years of REDACTED ng at Vng at 
a are mare m
CM doCM do
ttCOPYmm
t is plat is pl
e and e and 
This document(±2±2dd
(-(-1/1/cannot mm
hooseoose
ons wons w
dadbe the
maymay bbyyusedMainMai
e Mae Mtoableable
intntsupporton a on a
ation Peion P
le thetany m
on) inon) i
awmarketing osingsing
t with with
The doThe d
mg/kgmg/kauthorizationat leat le
Visit Visit 
met anmet a
gapplication rm
yy50 si50 syy
anned tnned
easand ubjub
med med anyt fofo
ject. ject. extensionshe safe saf
associassoci
ormormor variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 11 of 53age. The second age group will consist of at least 10 subjects between 1 month and <4 years of 
age. Since the primary objective of this open-label exploratory study is to assess the safety and 
preliminary efficacy of LCM in subjects with generalized seizures and other epilepsy syndromes, 
a sample size of 50 evaluable subjects is deemed adequate for meeting the objectives of the study. No formal sample size calculations were performed.
3 DATA ANALYSIS CONSIDERATIONS
3.1 General presentation of summaries and analyses
Statistical analysis and generation of tables, figures, subject data listings, and statistical output will be performed using SAS Version 9.4 or higher. All tables and listings will use Courier New 
font size 9. 
Descriptive statistics will be displayed to provide an overview of the study results. If not stated 
otherwise, all summaries will be displayed overall and by age group ( ≥ 1 month to <4 years, ≥4 
to <12 years, and ≥12 to <18 years). For categorical parameters, the number and percentage of 
subjects in each category will be presented. If not stated otherwise, the denominator for percentages will be based on the number of subjects in the respective population. Unless 
otherwise noted, all percentages will be displayed to 1 decimal place. No percentage will be 
displayed for zero counts, and no decimal will be presented when the percentage is 100%. For continuous parameters, descriptive statistics will include number of subjects (n), mean, standard 
deviation (SD), median, minimum, and maximum.
Decimal places for descriptive statistics will always apply the following rules:
!“n” will be an integer.
!Mean, SD, and median will use 1 additional decimal place compared to the original data.
!Coefficient of variance (CV[%]) will be presented with 1 decimal place.
!Minimum and maximum will have the same number of decimal places as the original value.
A complete set of data listings containing all documented data and all calculated data (eg, change 
from Baseline) will be generated, and will be sorted by site, subject number and visit (where applicable).
3.2 General study level definitions
3.2.1 Last dose of LCM
Unless otherwise noted, all references to the last dose of LCM in this SAP refer to the last dose 
of LCM within the study (eg, including the Taper Period). The last dose of LCM during the 
Treatment Period will be defined as the last dose during the Titration and Maintenance Periods.
3.2.2 Relative day
The relative day of a visit or an event with respect to the first intake of LCM will be presented in 
subject data listings. Relative day will be calculated as follows:
!If the visit/event date occurred prior to the first intake of LCM, the relative day is calculated 
as visit/event date minus first LCM dose date. In subject data listings, relative days based on 
this situation will be preceded by a ‘-‘.REDACTEDalwayalwa
1 addi1 addiCOPYclude lude
m.m.
This document3.2.2.2.2
TTcannotMwitwit
atmentment
22beerwierwi
hhused LastLasttonernersupportgg
nerateerate
ralraany s cont con
dmarketingitiontion
will bewill b
have haveauthorization ys appys app
onanaapplicationtive ve
place.place
when twhen
numbenumbandhe dee de
ep opoany onon
ber anber aextensionsCouriouri
sults. ults. 
nthnthooutpoutvariations tputhereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 12 of 53!If the visit/event date occurred on or after the first intake of LCM but prior to the last dose of 
LCM, the relative day is calculated as visit/event date minus first LCM dose date + 1.
!If the visit/event date occurred after the date of last dose of LCM, the relative day is 
calculated as visit/event date minus last dose date. In subject data listings, relative days based 
on this situation will be preceded by a ‘+’.
Relative days will not be presented for partial or missing dates.
3.2.3 Study periods
For the purpose of analyses, the following periods are defined.
!Baseline Period: 
The Baseline Period is defined as the period of time from the date of Visit 1 to 1 day prior to 
the date of first dose of LCM. For the definition of Baseline values see Section 3.3.
!Titration Period: 
The Titration Period is defined as the period of time from the date of first dose of LCM to the 
date of Visit 6 or the date of ET, whatever occurs first. If Visit 6 and ET are missing the Titration Period ends at the date of last dose of LCM.
!Maintenance Period: 
The Maintenance Period is defined as the period of time from the day after the date of Visit 6 
to the date of Visit 9/ET. If Visit 9/ET is missing the Maintenance Period ends at the date of last dose of LCM.
!Treatment Period:
The Treatment Period is defined as the combined Titration and Maintenance Period, ie, starts 
at the date of first dose of LCM and ends at Visit 9/ET. If Visit 9/ET is missing the 
Maintenance Period ends at the date of last dose of LCM.
3.2.4 Last Visit
The Last Visit for all assessments in SP0966 is the last non-missing assessment during the 
Treatment Period. This cannot be the same assessment as the baseline assessment. All scheduled 
and unscheduled assessments within this time period will be considered. Last Visit will be determined separately for each study procedure where Last Visit is mentioned within this 
document.
3.2.5 Age and age groups
The age (at enrollment) will be given in years (with 2 decimals) and will be derived with the 
following formula:
Age (years) = (date of informed consent - date of birth) / 365.25
Partial dates will not be completed. If it is not possible to calculate the age due to incomplete or 
missing date information the age as documented at Visit 1 will be used:
Age (years) = years part of age in CRF + (month part of age in CRF / 12)
If not stated otherwise, the following age groups will be used for the presentation of results: REDACTED eri
 missi missCOPY riod iod 
This documentollollocannot age age (a(
owiowibe usedaratelaratetossesssessupport essmessm
is canns cann
smany marketing s the cothe co
and enand e
he date daauthorization of timof tim
ing thng thapplicationdat
sit 6 asit 6 aand te ofe ofany extensions 1 to 1 to 11
ectioectioor variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 13 of 53!≥ 1 month to <4 years, 
!≥4 to <12 years, and 
!≥12 to <18 years.
For the derivation of (markedly) abnormal values (see Sections 8.5, 8.6.1, and 8.6.2 ) the age at 
assessment will be used. This will be derived as follows:
!For subject with a complete date of birth, use the date of birth to calculate the age at the time 
of measurement.
!For subject with a partial date of birth with available information about year and month, use 
the first day of the month to impute the date of birth and use the imputed date of birth to 
calculate age at the time of measurement.
!For subject with a partial date of birth with available information about year only, use age as 
given in the eCRF and add the time between measurement and informed consent (ie, [date of 
measurement – date of informed consent] / 365.25).
3.3 Definition of Baseline values
Unless otherwise specified, Baseline will be based on the last nonmissing data collected prior to the first dose of LCM, ie, assessments on Visit 1 or Visit 2. It is possible that values measured on the day of first dose of LCM (Visit 2 [start of Titration Period]) are assigned to the Baseline 
Period for summary purposes.
3.4 Protocol deviations
Important protocol deviations are deviations from the protocol which could potentially have a 
meaningful impact on the primary or secondary safety outcomes or preliminary efficacy outcomes for an individual subject. The criteria for identifying important protocol deviations and 
the classification of important protocol deviations will be defined separately in the Specification
of Protocol Deviations (SPD) document. To the extent feasible, rules for identifying protocol deviations will be defined without review of the data and without consideration of the frequency 
of occurrence of such deviations. Whenever possible, criteria for identifying important protocol 
deviations will be implemented algorithmically to ensure consistency in the classification of important protocol deviations across all subjects.
Important protocol deviations will be reviewed as part of the Data Evaluation Meeting (DEM) 
prior to database lock.
3.5 Analysis sets
The analysis set for subject disposition will be based on All Subjects Screened. Safety variables will be summarized for the Safety Set (SS); efficacy variables will be summarized for the Full Analysis Set (FAS). Select PK analysis may be based on the Pharmacokinetic Per-Protocol Set 
(PK-PPS). All other parameters will be summarized using the SS.
3.5.1 Safety Set
The primary analysis set will be the SS and will include all enrolled subjects who take at least 
1 dose of LCM.REDACTED iationiation
r secr secCOPYVisitVisi
ration ration
This document will ll
AnaAna
(P(cannot analanalyy
lb ebebe usedocol dol d
ase loase loto dev
dsupportviationation
lementemen
viativiatanyocuocu
hout rhout marketingcondaconda
The crithe cri
tocol docol 
umeumauthorizationn PerPer
s fromfromapplication st nonmt non
2. . ItIt is  i
eriodriodand any yeye
med comed cextensionsmonmon
of birtof birt
eear aror nthnthvariations time ime thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 14 of 533.5.2 Full Analysis Set
The analysis set for the preliminary efficacy variables will be the FAS and will include all 
subjects in the SS having had a Baseline and at least 1 post-Baseline efficacy related assessment.
3.5.3 Pharmacokinetic Per Protocol Set
The PK-PPS will consist of all subjects from the SS having provided at least 1 measurable 
post-dose plasma sample (with recorded sampling time) on at least 1 visit with documented LCM intake times.
3.6 Treatment assignment and treatment groups
All subjects treated in this study receive LCM at doses ranging between 2mg/kg/day (or 100 mg/day) to 12 mg/kg/day (or 600 mg/day). Summaries will be presented based on total 
number of subjects and will generally not be differentiated by LCM dose. Where appropriate, 
LCM dose will be presented on subject data listings.
3.7 Center pooling strategy
No data pooling strategies will be applied for analyses for this study. Unless otherwise stated, data from all sites will be combined and summarized collectively.
3.8 Coding dictionaries
Medical history and AEs will be coded using the Medical Dictionary for Regulatory Affairs (MedDRA
®) Version 16.1. Medications and therapies will be coded using the World Health 
Organization Drug Dictionary (WHO-DD) version September 2013. Medical procedures will not 
be coded.
3.9 Changes to protocol-defined analyses
Not applicable.
4 STATISTICAL/ANALYTICAL ISSUES
4.1 Adjustments for covariates
Not applicable.
4.2 Handling of dropouts or missing data
4.2.1 Visit mapping in case of premature discontinuation
Subjects who prematurely discontinue the study will be evaluated based on the data collected at 
each visit attended. For these subjects, the early termination visit will be mapped to the next 
scheduled visit, ie, the assessments documented at Visit 9/ET will be assigned to the next 
scheduled visit, for which the corresponding assessment is scheduled, following the last documented visit.
4.2.2 Missing data
With respect to AEs, events with missing intensity will be assumed to be severe. Events with 
missing relationship to LCM per the investigator will be assumed to be related.
To assess the change and percent change in seizure days for any generalized seizures from the 
Baseline Period to the Maintenance Period for subjects who prematurely discontinue the study, a herahera
)versiversi
ocolocolCOPY MediMedi
pii
This document hh
docudocu
4cannotit att at
duled uled 
eduledulbeho ho pp
ttetteusedVisitVisit
pretondlndlsupport ntsnt
linginany LL
s fosf omarketing-dede
//ANANauthorizationdical dical 
pies wies wi
on on SeSe
efefapplication udydy. U. 
elly.y.
DiDand UUany extensions ayy(or (or 
ased onsed on
here ahere aor variations CM M thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 15 of 53last observation carried forward convention will be applied in the following manner to obtain an 
estimate for the Maintenance Period:
!Subjects discontinued prematurely during the Titration Period: estimates will be calculated 
using all available data in the Titration Period and carried forward for the Maintenance 
Period. 
!Subjects discontinued prematurely during the Maintenance Period: estimates will be 
calculated using all available data in the Maintenance Period and carried forward for the 
entire Maintenance Period. 
!Subjects completing the Maintenance Period: estimates will be calculated using all data from 
the Maintenance Period.
Missing values for other safety or preliminary efficacy variables will be not imputed. 
No imputation of missing values associated with an individual date or visit is planned, with the 
exception of partial date information for AEs and medications in order to determine whether they 
are treatment-emergent or concomitant, respectively, and for medical resources to define in 
which study period these were used. For details see Section 4.2.3 .
4.2.3 Incomplete or missing dates for adverse events and concomitant 
medication
For analyses of AEs and concomitant medication usage, a complete date must be established in 
order to correctly identify the AE or medication as occurring during treatment in the study or not. For the purposes of imputing missing components of partially-reported start and stop dates for 
AEs and for medication use, the algorithms listed below will be followed. Start and stop dates of 
AEs or concomitant medication will be displayed as reported in the subject data listings (ie, no imputed values will be displayed in data listings).
!Missing start day, but month and year present:
If the start of LCM occurred in the same month and year as the occurrence of the 
AE/concomitant medication, the start day of the event/concomitant medication will be 
assigned to the day of first administration of LCM.
Otherwise the start day will be set to the 1
stday of the month.
!Missing start day and month, but year present:
If the start of LCM occurred in the same year as the occurrence of the AE/concomitant 
medication, the start day and month will be assigned to the date of first administration of LCM.
Otherwise the start day and month will be set to January 1
st.
!Missing end day, but month and year present:
The end day will be set to the last day of the month.
!Missing end day and month, but year present:
The end day and month will be set to the date of study termination or the date equivalent to 
30 days after last dose of LCM, whatever occurs later.REDACTEDon ason a
ponenponen
hms lihms li
be disbe di
datadatCOPY n usagusa
This document !!cannot cata
CMM..
OthOthbe rt
ationationusedt dayday
t of of LLto yysupport atiotio
f first afirst
rt dayt dayanyd in d in
on, thon,marketing splpl
ta listina listin
nd yd yeare
thtauthorizationge, a ge, a 
occuroccur
nts of ts of 
isted bsted b
layayapplication .
se evese ev
coand to to
al resol resoanyt is pt is 
o detedeextensionsall dall d
mputempute
por attvariations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 16 of 53However, if the study termination year and year for the date which is 30 days after the last 
Dose of LCM are greater than the event/concomitant medication year, the day and month are 
to be set to December 31st.
An AE with a completely missing start date will be considered treatment-emergent if the end 
date of the AE is not on or before the date of first dose of LCM.
With respect to the definition of medication as concomitant, the following rule will be applied in 
case of completely missing stop and/or start date information:
Medications with a missing stop date and a start date prior to the date of last administration of 
LCM will be considered as concomitant medication. Medications with a missing start date whose 
stop date is either unknown or after the date of the first application of LCM will be considered as concomitant medication, but not as prior medication. Medications with missing start date whose 
stop date is prior to first administration of LCM will be considered as prior medication, but not 
as concomitant medication.
4.2.4 Incomplete dates for the last administration of LCM
For purposes of imputing missing components of partially reported dates for the last 
administration of LCM, the algorithms listed below will be followed. Stop dates of LCM will be 
displayed as reported in the subject data listings (ie, no imputed values will be displayed in data listing).
!Missing last administration day, but month and year present:
The last administration day will be set to the last day of the month or the date of the final 
contact, whichever is earlier in the month.
!Missing last administration day and month, but year present:
The last administration day will be set to the last day of the year or the date of the final 
contact, whichever is earlier in the year.
!Completely missing date of last administration:
The last administration date will be imputed for the duration of exposure only as the date of 
last contact according to the study termination form. A review of the data will be performed to ensure that the imputation does not result in an unrealistic value for duration of exposure.
If a subject died during the study, and the imputed last administration date according to the rules 
above is after the date of death, the last administration date will be assigned to the date of death.
4.3 Interim analyses and data monitoring
No formal interim analysis is planned for this study; however, data will be presented to and reviewed by a DMC. The objectives and procedures for the DMC will be detailed in the DMC Charter.
4.4 Multicenter studies
Unless otherwise stated, descriptive summaries for individual sites will not be presented. Subject data listings will provide data grouped by site.REDACTED anan
to the to the
monthmonth
and mand mCOPY o io 
nd ynd
This document evievie
ChaChacannot formaorma
ewewbe er sedd duridur
the the tohe imhe imsupport n dadatet
ing to ng to
impumpanyof lastof lasmarketingmonthmont
be set te set 
n the ythe authorization year pear p
e last dlast d
.
ththapplication ed dad da
llowedowed
uted vauted vandf LCLC
attany CMCMextensionst datda
e conscons
 start start 
medicaedicaor onon
atetevariations in n 
no fno fthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 17 of 534.5 Multiple comparisons/multiplicity
There will be no adjustment for multiplicity in this study.
4.6 Use of an efficacy subset of subjects
Not applicable.
4.7 Active-control studies int ended to show equivalence
Not applicable
4.8 Examination of subgroups
If not stated otherwise, summaries will be presented by age groups as given in Section 3.2.5 . 
Separate age subgroupings are used for the purpose of summaries of questionnaires with 
different versions according to the age of the subject. Details are described in the corresponding 
sections describing the analysis of the questionnaires.
The following syndrome subgroups will be used to investigate AEs and seizure days: 
!Infantile spasms/West syndrome
!Lennox Gastaut syndrome
!Dravet Syndrome
!Other symptomatic generalized epilepsy
!Primary generalized epilepsy
The classification of subjects to the syndromes will be done by a medical review and agreed 
during the DEM. Only subgroups with at least 4 subjects will be presented.
For the presentation of summaries by syndrome subgroups, the syndrome subgroups will be used 
instead of the age groups, ie, summaries will not be presented by syndrome and age group.
5 STUDY POPULATION CHARACTERISTICS
5.1 Subject disposition
The number of subjects screened, and the number and percentage of those subjects who were 
screen failures, broken down by primary reason for screening failure, will be presented for all 
subjects screened.
An overall summary of disposition for the SS will present the number and percentage of subjects 
completing the study and subjects discontinuing along with the reason for discontinuation. This 
summary will be presented overall as well as for the Titration Period and the Maintenance 
Period. The disposition summary will be repeated by syndrome subgroups (as described in Section 4.8).
The number and percentage of subjects who discontinued due to AEs broken down by type of 
AE will be presented overall only (ie, not by age group). The type of AE will be derived by combining outcome (fatal or not) and seriousness (serious or not) of all these AEs (for several 
AEs, if applicable) as given in the UCB Standard TFL Shells (see Table DS T 04). REDACTED yyndrondroyyy
ith aith aCOPY 
This documentPerioerio
SecSeccannotll ll 
eting ting 
mmarymary
oddbe sumsumusedbrokrok
ned.ned.tojectect
kenkensupport OO
ct ddispis
ts scts sany PULPULmarketingom
at leasat leas
byyssyyyndyn
mariemariauthorization mes wes wapplication andand send seany extensions tion 3ion 3
naires aires 
n thetheor variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 18 of 53The date of first subject in, date of last subject out, number of screened subjects, and the number 
of subjects in each analysis set (SS, FAS, and PK-PPS) will be summarized overall and by site
for all subjects screened. Subjects who transferred sites will be summarized according to their 
original site. The summary by site will not be presented by age groups.
Additionally, the number and percentage of subjects in the different analysis sets (SS, FAS, and 
PK-PPS) will be provided.
5.2 Protocol deviations
Important protocol deviations defined in the SPD, and additionally identified at the DEM before database lock, will be listed for the SS. 
The number and percentage of subjects with at least 1 important protocol deviation will be 
summarized overall and by category of important protocol deviation for the SS. The number and 
percentage of subjects with no important protocol deviations will also be presented in this 
summary. This summary will not be presented by age group.
6 DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS
6.1 Demographics
The BMI will be calculated using the formula
BMI = weight (kg) / (height (m))2.
The following demographics will be summarized for the SS:
!Age (years) – continuous and categorized as (28 days - <24 months, 24 months - <12 years, 
12 years - <18 years)
!Gender (male, female)
!Race (American Indian/Alaskan Native, Asian, Black, Native Hawaiian or Other Pacific 
Islander, White, Other/Mixed)
!Ethnicity (Hispanic or Latino, not Hispanic or Latino)
!Height (cm)
!Weight (kg)
!BMI (kg/m2)
!Head circumference (cm)
The demographics summary will be repeated by syndrome subgroups (as described in 
Section 4.8).
6.2 Other Baseline characteristics
The time since first diagnosis will be given in years (with 2 decimal places) and will be derived 
with the following formula:
(Date of informed consent - date of diagnosis) / 365.25REDACTED marizemarize
egorizegorizCOPY 
This documentSectiecti
66cannotad cird cir
e demdembeg/m/mused )
m2)m2)to support or Latior Latany kaka
xed)xed)marketing an Nan Nauthorization ed fored for
d as d as application and INE NE any esesextensions on wiln wi
S. The. The
sentsentor bbvariations befobefothereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 19 of 53Partial dates will be imputed. If the month and year are available, the diagnosis date is imputed 
as the later of the following dates: the first day of the month, the subject’s birthdate, or the date 
of the first seizure (if available). If only a year is available, the later of the following dates will 
be imputed: January 1stof the year, the subject’s birthdate, and the date of the first seizure. 
Completely missing dates will not be replaced and the time since first diagnosis will be set to 
missing.
The age at first diagnosis will be derived using the same formula as age (see Section 3.2.5 ) but 
using the date of first diagnosis of disease instead of the date of informed consent. Partial dates 
of first diagnosis will be completed as described for the time since diagnosis. If the date of birth 
is incomplete, the age at first diagnosis will be derived as follows:
!For subject with a partial date of birth with available information about year and month, use 
the first day of the month to impute the date of birth and use the imputed date of birth to 
calculate age at first diagnosis.
!For subject with a partial date of birth with available information about year only, use age as 
given in the eCRF and subtract the time between (imputed) date of diagnosis and informed 
consent (ie, [date of informed consent – date of diagnosis] / 365.25).
Completely missing dates will not be replaced and the age at first diagnosis will be set to 
missing.
Antiepileptic drugs will be defined as medications documented on the “Concomitant 
Medications (AEDs only)” log form. A medical review will be performed to ensure that the 
medications are documented correctly. Corrective measurements (correction of documentation or 
programmatic mapping to the correct medication category [AED or not]) will be applied as applicable. Concomitant AEDs at Baseline will be defined as all concomitant AEDs given on the 
date of first dose of LCM. Medications will be counted only once per unique WHO-DD 
preferred name.
The following Baseline characteristics will be summarized for the SS:
!Time since first diagnosis (years)
!Age at diagnosis (years)
!History of withdrawal seizures (yes, no)
!History of status epilepticus (yes, no)
!Number of concomitant AEDs at Baseline (1, 2, 3)
The ILAE Seizure classification (1981) history for the last 12 months will be summarized for the 
SS presenting number and percentage of subjects with the following categories:
!Partial-onset seizures
∀Simple partial with motor signs (I A1)
∀Simple partial with somatosensory or special sensory symptoms (I A2) 
∀Simple partial with autonomic symptoms or signs (I A3)
∀Simple partial with psychic symptoms (I A4)REDACTEDcal recal r
orrectivrrectiv
medicamedica
aselinaselin
nsnCOPY ns dons do
This document !!Pcannot LAE SLAE 
presepresebeer of er ofused statusstatustodrawdrawsupportsis (is (
years)ears)
waany risri
(y(yeamarketing e ww
s will bwill b
isticssticauthorizationocumecume
view view 
ive meve me
ation ction c
willwilapplication365.25365.2
t first dfirst andaboubou
of diof diany ut yut yextensions and mand m
date oate oor of bof variations ut 
datesates
birbithereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 20 of 53∀Complex partial (I B)
∀Partial evolving to secondarily generalized (I C) 
!Generalized seizures
∀Absence (II A) 
∀Myoclonic (II B) 
∀Clonic (II C) 
∀Tonic (II D) 
∀Tonic-clonic (II E) 
∀Atonic (II F) 
!Unclassified epileptic seizures
∀Unclassified epileptic seizures (III)
The historical seizure count form of the electronic Case Report form (eCRF) records the number 
of seizures per pre-selected ILAE seizure code experienced by the subject during the 4 weeks 
prior to the start of the study. These data will be provided in a subject data listing.
A listing of reproductive potential and birth control measures for female subjects will be 
provided.
6.3 Medical history and concomitant diseases
The number and percentage of subjects with a medical history condition, including both resolved 
and ongoing conditions at the time of study entry, will be summarized overall and by MedDRA®
primary system organ class (SOC) and preferred term (PT) for the SS.
6.4 Prior and concomitant medications
Medications will be considered as prior if the start date of the medication is before the date of 
first dose of LCM. Medications will be considered as concomitant if it was taken at least once during treatment with LCM (ie, from the date of first administration of LCM through the date of 
last administration of LCM). Medications starting prior to first dose of LCM and continuing 
during treatment with LCM will be considered both, prior and concomitant medication.
For cases of partial or missing dates the rules described in Section 4.2.3 will be applied.
The number and percentage of subjects taking concomitant AEDs will be summarized by 
WHO-DD chemical subgroup (Level 4) and preferred drug name for the SS. 
The number and percentage of subjects taking prior and concomitant medications (excluding 
AEDs) will be summarized separately by WHO-DD anatomical main group (Level 1) and 
therapeutic subgroup (Level 2) for the SS. 
Vagus nerve stimulation will only be listed.REDACTED oncoonco
ts withts with
of stuof stuCOPY ided
ol meaol me
This documenthe he
AEDAED
ththannot bebe
DD cDD c
e numnumbe er aner anused wiwi
artialartialtof
ith Lith support tionsion
CMCM((i
LLCMCMany d as pd as 
swmarketingudyudy en eyy
d prefed pref
omitaomiauthorizationasuasu
omitamita
h a mea meapplicationorm (orm 
y the suthe sy
n a suba su
uresuresand ((any extensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 21 of 537 MEASUREMENTS OF TREATMENT COMPLIANCE
7.1 Derivation of compliance
Actual weight of LCM oral solution will be calculated at each visit using the following formula:
Actual weight of used oral solution (g) = Total weight of bottles (including caps) at 
Dispensation - Total weight of bottles (including caps) at Return 
The actual weight used will also be determined for the Titration Period, Maintenance Period, and 
the entire Treatment Period by summing up the respective single actual weights. 
The following formula will be used to calculate the expected weight of oral solution for the 
respective LCM dose:
Expected weight of used oral solution (g) = Daily prescribed oral solution (mL) x Number of 
days between visits x 1.1g/mL. (The estimated weight of 1mL of LCM is 1.1g.)
The expected weight will also be determined for the Titration Period, Maintenance Period, and 
the entire Treatment Period by summing up the respective single expected weights. 
A subject’s dosing compliance should be within 75-125% during each visit. Compliance to LCM
dosing will be calculated for each visit, and will also be determined for the Titration Period, 
Maintenance Period, and the entire Treatment Period. 
For oral solution, compliance will be calculated using the following formula:
Compliance (%) = Actual weight of used oral solution (g) / Expected weight of used oral 
solution (g) x 100
For tablets, compliance will be calculated using the following formula:
Compliance (%) = (100 x [number of 100 mg tablets dispensed – number of 100 mg tablets 
returned] + 50 x [number of 50 mg tablets dispensed – number of 50 mg tablets returned]) / 
dose given on the Drug accountability form of the eCRF x number of days)) x 100
7.2 Presentation of compliance
Compliance will be summarized separately for the Treatment Period, the Titration Period and the Maintenance Period. It will be presented with descriptive statistics and additionally categorized as <75%, ≥75% to ≤125%, and >125% 
8 SAFETY ANALYSES
All safety analyses will be conducted for the SS.
8.1 Primary safety variables
8.1.1 Generalized spike-wave discharges
The actual values of generalized spike-wave discharges per interpretable hour on 24-hour 
ambulatory EEG as well as changes from Baseline will be summarized descriptively by visit.
Furthermore, a frequency table will be presented for the number of subjects with an increase of 
at least 30% and an increase of at least 50% at Visit 6 compared to Baseline.REDACTED d oral d oral
lated ulated u
ererCOPY d. d. 
using using 
This document.1.11.1
ThThcannot y aa
11be analanalused SASAFFto≤≤1212support oo
mmarizemariz
It willt wil
5%any n ofn ofmarketing us
of of 100100
mg tabmg ta
ntabilntabauthorizationthe fthe 
solutisoluti
sing ing application ng eachg each
rminedrmine
fofand MaMa
pectedectedany is s
ainteninteextensionsfor tor t
(mLmL))
s 1.11.1or thethvariations d, and and thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 22 of 538.1.2 Generalized seizures
Days with any generalized seizures per 28 days (GSD/28d) will be based on the seizure diary and 
will be derived separately for the Baseline Period, the Titration Period, and the Maintenance 
Period. Basis for the calculation will be the number of days with at least 1 generalized seizure 
(GSD) (absence, myoclonic, clonic, tonic, tonic clonic, atonic, partial evolving to secondarily generalized) during the considered study period and the number of days in the considered study 
period for which seizure information was provided (D):
GSD/28d = GSD x (28/D)
The days with any generalized seizures per 28 days will only be derived for subjects who 
completed or discontinued during the respective study period. For subjects who discontinued 
during the Titration Period, the missing value of the Maintenance Period will be imputed as described in Section 4.2.
Descriptive statistics will be provided for actual values and changes from Baseline for days with 
any generalized seizures per 28 days by study period. This summary will be repeated by syndrome subgroups (as described in Section 4.8).
8.2 Secondary safety variables
8.2.1 3Hz spike-wave discharges
The actual counts of 3Hz spike-wave discharges (during waking hours) on 24-hour ambulatory 
EEG as well as changes from Baseline will be summarized descriptively by visit.
Furthermore, a frequency table will be presented for the number of subjects with an increase of 
at least 30% and an increase of at least 50% at Visit 6 compared to Baseline.
8.2.2 Adverse events
Treatment-emergent AEs (TEAE) are defined as those events which start on or after the date of 
first LCM administration and within 30 days following the date of last LCM administration, or 
whose severity worsens within this time frame. 
Other significant AEs are defined in Appendix 13.1 (Table 13-1 ).
An overall summary of AEs will provide the numbers and percentages of subjects with at least 
1 TEAE, serious TEAE, other significant TEAE, TEAE that led to discontinuation, drug-related TEAE, drug-related serious TEAE, severe TEAE, AE leading to death, and TEAE leading to 
death. The AE overall summary will be repeated by syndrome subgroups (as described in 
Section 4.8).
The following summaries of AEs will be provided by primary SOC and PT:
!TEAEs
!TEAEs during the Titration Period
!TEAEs during the Maintenance Period
!TEAEs by syndrome subgroups (as described in Section 4.8)
!TEAEs including subject numbersREDACTEDe sume sum
esenteesente
t 50% t 50%COPY (durin(durin
mm
This document T
!!cannot followollow
TETEbe AE
88).).usedated ted 
E oveE ovtoEAEEAEsupportdefindefin
of AEsf AEs
EEanythis thismarketing are defire def
hin 30hin 3authorizationng wng w
marizmariz
ed for ed for
at Viat Viapplication wakandwill bwill anym BBaseas
bebextensionswhowho
sconticonti
e impuimpor oovariations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 23 of 53!Serious TEAEs
!Serious TEAEs including subject numbers
!TEAEs leading to discontinuation
!TEAEs leading to discontinuation including subject numbers
!TEAEs by maximum intensity
!Nonserious TEAEs 
!Nonserious TEAEs occurring in > 5% of subjects
!Other significant TEAEs
The following summaries by primary SOC and PT will be presented overall only (ie, not by age 
group).
!TEAEs by relationship to LCM
!Serious TEAEs by relationship to LCM
!Nonserious TEAEs by relationship to LCM
!Fatal TEAEs by relationship to LCM
!Nonserious TEAEs occurring in at least 5% of subjects by relationship
8.3 Exploratory safety variables
A frequency table will be presented for the number of subjects with a decrease of at least 30% 
and a decrease of at least 50% in generalized spike-wave discharges on 24-hour EEG at Visit 6 
compared to Baseline by syndrome subgroups
8.4 Extent of exposure
The duration of LCM exposure for each study period will be calculated as follows:
Duration of LCM (days) = date of last dose of LCM during the respective period minus the 
date of first dose of LCM during the respective period plus 1.
For the calculation of the mean daily dose during the Maintenance Period, the total dose for each 
entry in the LCM administration form with at least 1day within the Maintenance Period will be 
calculated as follows:
Total dose = (Morning dose + evening dose) x (administration stop date - administration start 
date + 1)
If the administration start date is before the start date of the Maintenance Period the start date of 
the Maintenance Period will be used instead. If the administration stop date is after the end date 
of the Maintenance Period the end date of the Maintenance Period will be used instead.
The mean daily dose during the Maintenance Period will be calculated as the sum of the total 
doses for each entry in the study medication administration form with at least 1 day within the 
Maintenance Period divided by the duration of LCM exposure during the Maintenance Period.
Days during an analysis period with unknown dosing will be excluded from both the numerator and the denominator for the calculation of the mean daily dose.REDACTED ableable
the nuthe nu
neralizneraliz
subsubCOPY of subf sub
This documentth
the Mhe M
ofofcannotdod
te + 1e + 1
he ade adbe ose ose usedMadad
followollowto of tf t
dmdmsupport ys) = s) = 
LCLCMM
the theanyfor for
dadmarketing zeded
bgroupsgroup
sureure
eaauthorizationbjectsbject
ss
umberumber
d spds papplication band any extensions nlyly(ie(ieor variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 24 of 53The mean daily dose will be presented in mg/kg/day. For patients who received tablets, the mean 
daily dose will be normalized by the baseline weight.
The duration of LCM exposure will be summarized with descriptive statistics overall (ie, for the 
entire Treatment Period) as well as separately for each study period (Titration Period, Maintenance Period). 
In addition, the duration of LCM exposure will be summarized in 14-day categories up to the 
scheduled duration of the period:
!Treatment Period: ≤14 days, >14- ≤28 days, >28- ≤42 days, >42- ≤56 days, >56- ≤70 days, 
>70-≤84 days, >84- ≤98 days, >98- ≤112 days, >112- ≤126 days, >126- ≤140 days, 
>140-≤154 days, >154- ≤168 days, and >168 days. 
!Titration Period: ≤14 days, >14- ≤28 days, >28- ≤42 days, and >42 days.
!Maintenance Period: ≤14 days, >14- ≤28 days, >28- ≤42 days, >42- ≤56 days, >56- ≤70 days, 
>70-≤84 days, and >84 days. 
The mean daily dose during the Maintenance Period will be summarized descriptively.
8.5 Clinical laboratory evaluations
The following laboratory parameters are measured within the study:
!Hematology: red blood cell count, white blood cell count, differential count (lymphocytes, 
basophils, eosinophils, monocytes, neutrophils), platelet count, hematocrit, and hemoglobin
!Chemistry: calcium, serum electrolytes (sodium, potassium, chloride, bicarbonate), total 
protein, albumin, phosphate, glucose, uric acid, alkaline phosphatase, urea nitrogen, 
creatinine, aspartate aminotransferase, alanine aminotransferase, gamma glutamyltransferase, 
total bilirubin, cholesterol, triglycerides
!Urinalysis: albumin, specific gravity, ketones, glucose, pH, microscopic exam for blood cells 
or casts/high power field
!Endocrinology: FSH, LH, T3, T4, TSH
Markedly abnormal laboratory values are defined in appendix 13.2. Treatment-emergent 
markedly abnormal (TEMA) values are defined as those markedly abnormal values which occur 
during the Treatment Period (including unscheduled visits), ie, with a normal Baseline value.
Observed values and changes from Baseline will be summarized for the parameters of 
hematology, chemistry and endocrinology given above. The Last Visit and minimum and 
maximum post-Baseline values during the Treatment Period will also be presented in these 
summaries. Repeated or unscheduled laboratory assessments during the study will not be presented in the by-visit summaries, but will be considered when determining the Last Visit, 
minimum post-Baseline value, and maximum post-Baseline value.
The number and percentage of subjects with a TEMA value, TEMA low value, and TEMA high 
value will be summarized by parameter and visit. Percentages will be based on the number of 
subjects with a nonmissing value at the respective visit. Additionally, a list of subjects with at 
least 1 TEMA value will be provided including all laboratory measurements of the respective parameter of the respective subject.REDACTEDophilsphil
es (soes (so
ose, urose, ur
feraseferaseCOPYwithinwithi
od celd ce
))
This documentpreserese
minmicannot ogygy
mum pum p
mmarimaribe alu
yy, ch, chusedmenmen
ues aues atol (TE (T
nttsupportLH, TLH, T
aboratoborato
TEMTEany T3Tmarketinge, alae, ala
eridesides
gravitgravit yauthorizationll coull cou
), plat, plat
odiumdium
iccaciaciapplication mari
the stuthe st
unand rizedizeanydaydayextensions yorayaysvariations ssthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 25 of 53Urinalysis and pregnancy test results will only be listed.
8.6 Vital signs, physical findings, and other observations related to 
safety
8.6.1 Vital signs, body weight, height, BMI, and head circumference
Markedly abnormal vital signs values are defined in Table 8‒1. 
Table 8‒1: Vital Signs Abnormality Criteria
Parameter Age Range Abnormality Criteria
Pulse Rate (beats/minute) <6m <100, >180
6m - <3y <90, >150
3y - <12y <60, >130
12y - <17y ≤50, ≥120
≥17y ≤50 and a decrease from Baseline of ≥15
≥120 and an increase from Baseline of ≥15
Systolic BP (mmHg) <6m <60, >100
6m - <3y <70, >120
3y - <12y <80, >140
12y - <17y <90, >160
≥17y ≤90 and a decrease from Baseline of ≥20
≥180 and an increase from Baseline of ≥20
Diastolic BP (mmHg) <6m <40, >65
6m - <3y <45, >75
3y - <12y ≤50, ≥80
12y - <17y ≤50, ≥105
≥17y ≤50 and a decrease from Baseline of ≥15
≥105 and an increase from Baseline of ≥15
Temperature All >1010F (38.30C)
Body Weight 1 month - <17y <3% or >97% of the normal body weight
growth curve ranges1based on gender and the
age of subject on date of weight assessment
≥17y ≥10% change from Baseline (an increase or a
decrease)
1source: http://www.cdc.gov/growthcharts/html_charts/wtage.htm
BP=blood pressure, m=month, y=year. 
A month is defined as 30 days; a year is defined as 365.25 days.REDACTED 7y7yTE
yyACCOPY <60<60
<7<PY
COCOCOCOC
This document en
umcannoteightightbe ttbeused seto support or
upany 66
n3nnnyanmarketing mmet
6m 6mmaauthorization 70, >0, >
<80<80on
izizizizriz
thapplication easas
n increincr
10000ca
>12>12ppand se fse fndany nyextensions s 
s
xtor variations vthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 26 of 53Observed values and changes from Baseline for vital signs (systolic BP, diastolic BP, and pulse 
rate) will be summarized by visit and position/time point including the Last Visit.
Changes of standing measurements versus supine measurements of systolic BP, diastolic BP, and 
pulse rate will also be summarized for each visit and time point including the Last Visit.
Observed values and changes from Baseline for body weight, height, BMI, and head 
circumference will be summarized by visit. The Last Visit will also be presented in this 
summary.
The number and percentage of subjects with a markedly abnormal value, markedly abnormal low 
value, and markedly abnormal high value will be presented by visit. Percentages will be based on 
the number of subjects with a nonmissing value at the respective visit. Additionally, a list of subjects with at least 1 markedly abnormal value will be provided including all vital sign 
measurements of the respective subject.
8.6.2 Electrocardiograms
Abnormality criteria to be used in the determination of ECG abnormalities are defined in 
Table 8‒2, where increase and decrease are relative to Baseline values:
Table 8‒2: Electrocardiogram Abnormality Criteria
Parameter Age Range Abnormality Criteria
QT interval (ms) 1m-<12y ≥500
≥12y ≥500 or ≥60ms increase from Baseline
QTc(F) (ms) <6m >490, or >15% increase from Baseline
6m-<17y >440, or >15% increase from Baseline
≥17y ≥500 or ≥60ms increase from Baseline
QTc(B) (ms) <6m >490, or >15% increase from Baseline
6m-<17y >450, or >15% increase from Baseline
≥17y ≥500 or ≥60ms increase from Baseline
PR interval (ms) <6m >150, or ≥25% increase from Baseline
6m-<3y >170, or ≥25% increase from Baseline
3y-<12y >180, or ≥25% increase from Baseline
≥12y - <17y >200, or ≥25% increase from Baseline
≥17y Treatment-emergent value >200, >220, >250
QRS interval (ms) 1m-<3y >90, or ≥25% increase from Baseline
3y-<12y >100, or ≥25% increase from Baseline
≥12y - <17y ≥110, or ≥25% increase from Baseline
≥17y Treatment-emergent value >100, >120, >140
Heart rate (bpm) <6m <100, >180REDACTED TE
AC
<1<RECOPY rr
APPPYOPCO
This document QRSQRSnt
mmmumcannot t
nnbe bused d
usto tsupport po
suany <6<
ananananyanmarketing 17y7yg
17y7yke
6m6maauthorizationAbnAbn
≥5≥5onatiz
thapplication aluesalue
iaatio
nornorppandalitiealitie
es:any extensionsbe bbe 
yy, a li, a li
vital svital orrmarm
babavariations malmalthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 27 of 53Table 8‒2: Electrocardiogram Abnormality Criteria
Parameter Age Range Abnormality Criteria
6m-<3y <90, >130
3y-<12y <60, >130
>12y <50, >120
bpm=beats per minute; m=months; ms=milliseconds; QTc=corrected QT interval; y=years. 
A month is defined as 30 days; a year is defined as 365.25 days.
Treatment-emergent ECG abnormalities are defined as values meeting the criteria given in 
Table 8‒2at any post-Baseline visit during the Treatment Period (including unscheduled visits) 
and not meeting the same criteria during Baseline.
For ECGs, baseline will be defined as the average of all pre-dose interpretable readings. For all 
post-baseline visits, the average of all interpretable readings at the specified visit will be used for summaries.
Observed results and changes from Baseline in ECG results will be summarized for all visits and 
the Last Visit.
The number and percentage of subjects with no abnormality, an abnormal but not clinically 
significant finding, and a clinically significant finding, will be summarized by visit, including 
last visit. Percentages will be relative to the number of subjects with an ECG assessment at the respective visit. Subjects are counted once at each visit based on the worst observed outcome 
across all abnormalities reported at that visit.
Summaries of shifts from Baseline to post-Baseline visits (including Last Visit) will also be 
provided based on the categories normal, abnormal, not clinically significant, and abnormal, 
clinically significant.
The number and percentage of subjects with treatment-emergent ECG abnormalities will be 
presented by visit and treatment group. Abnormalities reported at an unscheduled visit will be 
summarized under the scheduled visit preceding the unscheduled visit (if the abnormality was 
not present already at the preceding scheduled visit). Percentages will be based on the number ofnonmissing values for the variable and visit. In addition, a listing including all ECG parameter 
values for subjects meeting any abnormality criteria will be provided.
8.6.3 Physical and neurological examination
Summaries of shift from Baseline to Visit 9/ET will be provided based on categories normal, 
abnormal, not clinically significant, and abnormal, clinically significant for each of the single 
neurological examinations. Summaries of shift from Baseline normal to any post-baseline 
abnormal, clinically significant category for each of the neurological examinations will also be provided. For physical examination, summaries of shift from Baseline normal to any post-
baseline abnormal, clinically significant category will be presented. REDACTEDumbumb
at eacat eac
visitisit
o posto post
mmCOPYormaorma
nding,nding
beberr
This documentabnoabno
proprocannoties es 
mal, nmal, n
rologrologbe so fso fusedtssmm
PhPhto for 
memesupportheduleedul
the pree pr
r the theanyubjub
nt grnt gr
dmarketing t-BaB
mal, abnal, abn
bjectbjecauthorization, wilwil
r of suof su
ch visivisi
Baseasapplicationbe sube su
lityity, an, an
ll bll band anyblebl
ied viied vextensionsven iven 
heduleedule
le reeror iivariations nnn
iaonthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 28 of 538.6.4 Tanner stage assessment
The Tanner stage is a measurement for the subject’s sexual development used for subjects 
pubescent at Visit 1. It is a 3-item scale (for females: breasts, pubic hair, and overall stage; and 
for males: genitals, pubic hair, and overall stage) with 5 possible stages (I, II, III, IV, or V).
Shift tables will be produced showing the change in Tanner stage from Visit 1 to Visit 9/ET by 
gender for each of the 3 single items. Percentages will be based on the number of subjects with at 
least 1 nonmissing value at Visit 1 or Visit 9/ET. 
8.6.5 Achenbach Child Behavior Checklist
The Achenbach CBCL is a questionnaire intended to evaluate a child’s competencies and 
behavioral/emotional problems. Depending on the subject’s age, 1 of 2 versions of the 
Achenbach CBCL is used. The CBCL/1½-5 is intended for use in children 18 months to 5 years 
and 11 months of age at Baseline. For subjects ≥6 years to <18 years at Baseline, the CBCL/6-18 
will be used. For each subject, the same version that is used at Visit 2 (Baseline) should be used 
at all following visits.
The CBCL/1½-5 comprises 100 questions and the CBCL/6-18 comprises 120 questions with the 
response options of: 
!0=not true (as far as known)
!1=somewhat or sometimes true
!2=very true or often true
The CBCL/1½-5 will be grouped according to syndrome scales as given in Table 8‒1.
Table 8‒1: CBCL/1½-5 
Syndrome scale Questions
Aggressive behavior 8, 15, 16, 18, 20, 27, 29, 35, 40, 42, 44, 53, 58, 66, 69, 81, 85, 88, 96
Anxious/depressed 10, 33, 37, 43, 47, 68, 87, 90
Attention problems 5, 6, 56, 59, 95
Emotionally reactive 21, 46, 51, 79, 82, 83, 92, 97, 99
Sleep problems 22, 38, 48, 64, 74, 84, 94
Somatic complaints 1, 7, 12, 19, 24, 39, 45, 52, 78, 86, 93
Withdrawn 2, 4, 23, 62, 67, 70, 71, 98
Other problems 3, 9, 11, 13, 14, 17, 25, 26, 28, 30, 31, 32, 34, 36, 41, 49, 50, 54, 55, 57, 
60, 61, 63, 65, 72, 73, 75, 76, 77, 80, 89, 91, 100
The CBCL/6-18 will be grouped according to empirically based syndrome scales as given in 
Table 8‒2.REDACTED ding toding tCOPY 
This document meTTcannot awnwnt
er proer pronnbemplamplabused d
iniusto tosupport 1010
o5ooorpo
supany5, 15, 
0, 3303nymarketing onsnsket
16,16maauthorization o ssynynddapplication omprimprand risrisanyaselinaselinextensionses ands and
of the f the
monthmonth
line,ine,or variations at at thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 29 of 53Table 8‒2: CBCL/6-18 
Syndrome scale Questions
Aggressive behavior 3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 94, 95, 97, 104
Anxious/depressed 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
Attention problems 1, 4, 8, 10, 13, 17, 41, 61, 78, 80
Rule-breaking behavior 2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 101, 105, 106
Social problems 11, 12, 25, 27, 34, 36, 38, 48, 62, 64, 79
Somatic complaints 47, 49, 51, 54, 56a, 56b, 56c, 56d, 56e, 56f, 56g, 
Thought problems 9, 18, 40, 46, 58, 59, 60, 66, 70, 76, 83, 84, 85, 92, 100
Withdrawn/depressed 5, 42, 65, 69, 75, 102, 103, 111
Standardized T-scores are determined for each subject’s raw syndrome and overall scores based 
on the subject’s age and sex. Tables mapping each raw score to the appropriate T-score are 
provided in the CBCL Professional Manual and will be reproduced programmatically. 
For each questionnaire (CBCL/1½-5 and CBCL/6-18, respectively), calculated T-score values 
and change from Baseline for each CBCL syndrome as given in Table 8‒1and Table 8‒2, 
respectively, will be summarized by visit. The summaries will be presented by the 
questionnaire’s age groups (18 months to 5 years and ≥6 years to <18 years) instead of the ones 
defined in Section 3.2.5 .
8.6.6 BRIEF-P and BRIEF assessment
The BRIEF-P and BRIEF are validated tools that will be used for the evaluation of subjects ≥2 to 
<5 years of age, and ≥5 years of age, respectively. For each subject, the same version (BRIEF-P 
or BRIEF) that is used at Visit 2 (Baseline) should be used at Visit 9/ET.
8.6.6.1 BRIEF-P scores
The BRIEF-P form comprises 63 questions with entry options N (never: scored as 1 point), 
S (sometimes: scored as 2 points), and O (often: scored as 3 points).
The 63 items sum up to the raw Global Executive Composite (GEC) score which ranges from 63 
to 189. Higher scores are reflecting poorer functioning.
The 3 subscale scores and 5 individual component scores that make up these subscale scores are 
outlined in Table 8‒3.
Table 8‒3: BRIEF-P questionnaire scoring
Scale/Index Questions
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 60, 62
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46
Inhibitory self-control All from {Inhibit and Emotional Control}REDACTED yyearsears
asseass
tedtedCOPY , rer
me as gme as g
ummamma
This document ScaScant
umumumumcannotin in TT
bleble88becalecale
TaTausedu
scorescore
stoup toup tsupport prises 6rises 
as 2 pos 2 p
tany resresmarketing d tools ttools 
, resperesp
BaseliBaselauthorizationg
aries aries 
ndnd≥6≥6
essmssmapplication e apap
uced prced p
ectivelctive
iven iven andme ane an
apprpprany anynddextensions ns
10000ns
exor rvariations nnnon
ia
vthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 30 of 53Table 8‒3: BRIEF-P questionnaire scoring
Scale/Index Questions
Flexibility All from {Shift and Emotional Control}
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 59, 61, 63
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49
MI All from {Working Memory and Plan/Organize}
GEC Score 1-63
MI=Metacognition Index, GEC=Global Executive Composite
Standardized T-scores are determined from each subject’s raw GEC, Behavioral Regulation 
Index (BRI), Metacognition Index (MI), and component scores based on the subject’s age and 
sex. Tables that map each raw score to the appropriate T-score are provided in the BRIEF-P Professional Manual and will be reproduced programmatically.
Calculated T-score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF-P questionnaire will be summarized by visit for the respective age group ( ≥2 
to <5 years), ie, the age groups as defined in Section 3.2.5 will not be used.
8.6.6.2 BRIEF scores
The BRIEF form comprises 86 questions with entry options N (never: scored as 1 point), 
S (sometimes: scored as 2 points), and O (often: scored as 3 points).
The first 72 items sum up in the GEC score which ranges from 72 to 216, with higher scores 
reflecting poorer functioning.
The 2 subscale scores and 8 individual component scores that make up these subscale scores are 
outlined in Table 8‒4.
Table 8‒4: BRIEF questionnaire scoring
Scale/Index Questions
Inhibit 38, 41, 43, 44, 49, 54, 55, 56, 59, 65
Shift 5, 6, 8, 12, 13, 23, 30, 39
Emotional Control 1, 7, 20, 25, 26, 45, 50, 62, 64, 70
BRI All from {Inhibit, Shift, and Emotional Control}
Initiate 3, 10, 16, 47, 48, 61, 66, 71
Working Memory 2, 9, 17, 19, 24, 27, 32, 33, 37, 57
Plan/Organize 11, 15, 18, 22, 28, 35, 36, 40, 46, 51, 53, 58
Organization of Materials 4, 29, 67, 68, 69, 72
Monitor 14, 21, 31, 34, 42, 52, 60, 63
MI All from {Initiate, Working Memory, Plan/Organize, 
Organization of Materials, and Monitor}REDACTEDentent
ften: sften: s
core wcore wCOPY ntrytry
This documentWorkWork
PlPle
umucannot teeno
kikicabe n
be used troltroleto tosupport rt
ppanyionnionnmarketing al compal comauthorization y optiooptio
scoredcored
which whichapplicationexedxed
sit for tit for 
ill not ill noand ed sdsanyed ied innextensions ns
al Regal Reg
subjesubjeor rvariations nnnon
ia
vthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 31 of 53Table 8‒4: BRIEF questionnaire scoring
Scale/Index Questions
GEC Score 1-72
BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite
Standardized T-scores are determined from each subject’s raw GEC, BRI, MI, and component 
scores based on the subject’s age and sex. Tables that map each raw score to the appropriate 
T-score are provided in the BRIEF Professional Manual and will be reproduced 
programmatically.
Calculated T-score values and change from Baseline for the 2 indexed scores (BRI and MI), and 
GEC for the BRIEF questionnaire will be summarized by visit for the respective age group 
(≥5 years), ie, the age groups as defined in Section 3.2.5 will not be used.
9 ANALYSES OF EFFICACY VARIABLES
All analyses of preliminary efficacy variables will be conducted for the FAS.
9.1 Preliminary Efficacy Variables
9.1.1 Seizure days
Days with seizures per 28 days for each seizure type and study period will be calculated as 
described for the generalized seizures in Section 8.1.2 .
Percent change in seizure days is calculated as the respective seizure days per 28 days during the 
respective period (Titration Period and Maintenance Period) minus respective seizure days per 28 days during the Baseline Period divided by seizure days per 28 days during the Baseline 
Period and then multiplied by 100. 
Descriptive statistics will be used to summarize the observed values as well as absolute and 
percent changes from Baseline in seizure days per 28 days by study period (Baseline, Titration,
and Maintenance Period, respectively). Summaries will be provided for the following seizure 
types:
!Any generalized seizures (absence, myoclonic, clonic, tonic, tonic-clonic, atonic, partial 
evolving to secondarily generalized) 
!Absence seizures
!Myoclonic seizures
!Clonic seizures 
!Tonic seizures
!Tonic-clonic seizures
!Atonic seizures
9.1.2 Clinical global impression of change
The Clinical Global Impression of Change is a 7-point categorical rating scale in which the 
investigator assesses the subject’s change from Baseline in clinical status.REDACTED n n 8
d as thd as th
MaintMaint
divideddivideCOPY yype anpe a
8.181
This document !!cannot onic snic 
TTononbeonic onicused izurezuretoondondsupport eizureseizure
daridarany n s 
ectiveectivmarketing d bd b
o summo sum
seizuseizauthorizationnd sd s
.22..
the rese res
tenancnanc
bybyapplication studstudand the Fhe Fany extensions I and and 
ve age e ageor variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 32 of 53The number and percentage of subjects for each possible response of the Clinical Global 
Impression of Change will be presented. In addition, the 3 improvement values (very much 
improved, much improved, and minimally improved) grouped as “Improved” and the 3 
worsening values (minimally worse, much worse, and very much worse) grouped as “Worsened”, as well as the “No change” group will be summarized in the same way. Percentages 
will be based on the number of subjects with nonmissing values.
9.1.3 Caregiver’s global impression of change
The Caregiver’s Global Impression of Change is a 7-point categorical rating scale in which the 
caregiver assesses the subject’s change from Baseline in clinical status.
The number and percentage of subjects for each possible response of the Caregiver’s Global 
Impression of Change will be presented. In addition, the 3 improvement values (very much improved, much improved, and minimally improved) grouped as “Improved” and the 3 
worsening values (minimally worse, much worse, and very much worse) grouped as 
“Worsened”, as well as the “No change” group will be summarized in the same way. Percentages will be based on the number of subjects with nonmissing values.
9.1.4 Pediatric quality of life inventory
The PedsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric populations, including those with acute or chronic health conditions. The PedsQL Measurement Model consists of developmentally appropriate forms for pediatric subjects 
≥1 month to ≤12 months; ≥13 months to ≤24 months; >2 years to ≤4 years, ≥5 years to ≤7 years, 
≥8 years to ≤12 years, and ≥13 years to ≤18 years of age. For each subject, the same version that 
is used at Visit 2 (Baseline) should be used at Visit 9/ET.
PedsQL generic core scale scores will be calculated for each of the following 4 PedsQL scales:
!Physical Functioning
!Emotional Functioning
!Social Functioning
!School Functioning 
The PedsQL assessment is retrospective to the prior 4 weeks, and individual items are scored 
using a 5-point Likert scale (0 to 4 representing responses of: never, almost never, sometimes, 
often, or almost always). These scores of 0 to 4 will be transformed by the function: 100 –(response x 25) in order to generate scores of 0, 25, 50, 75, and 100 where a higher value 
represents a better health-related quality of life. 
Each scale score is then calculated as the mean of the corresponding nonmissing items if 50% or 
more of the items are nonmissing. The same algorithm will be used to calculate an overall Total 
Scale Score (all scales) and the Psychosocial Health Summary Score (a combination of the 
emotional, social and school functioning questions) for each subject.
Calculated values and change from Baseline for the total scale score and each of the 4 scale 
scores will be summarized by visit. For the presentation of the PedsQL summary, the 
questionnaire’s age groups ( ≥1 month to ≤12 months, ≥13 months to ≤24 months, ≥2 to ≤4 years, REDACTEDmonmon
8 y8 yearear
used atused at
ill beill beCOPYgeg
r chronr chro
yyapprappyy
th
This documentmoremore
SScacacannotnts ats a
h scalscal
eobex 25)x 25
bbusedLikerike
ost alwst alw
))tomenme
ertertsupport ent intany marketinge calce calcauthorizationropriropri
ths; >2hs; >2
ars of as of a
t VisitVisitapplication ric corec cor
nic heaic he
atand theheanygroupgrou
e sames aextensions r’s Gl’s Gl
(very(very
” and and 
upor variations h the h thethereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 33 of 53≥5 to ≤7 years, ≥8 to ≤12 years, and ≥13 to ≤18 years) will be used instead of the ones defined in
Section 3.2.5 .
9.1.5 Health care resource use
To assign the health resources to a specific study period (Baseline, Titration, and Maintenance, 
respectively), partial or missing dates will be imputed as described for AEs and concomitant medications in Section 4.2.3 . Hospital stays will be attributed to study periods based on the 
admission date. 
An event logged on the Hospitalization/ER Visit form of the eCRF where “Emergency room” is 
marked as initial entry point will be defined as an emergency room (ER) visit. An ER visit with a 
subject transfer to an inpatient general ward will also be counted as a hospitalization. However, 
all other instances of ER visits (where subject transfer is not to an inpatient general ward) will not be counted as hospitalizations.
For hospital stays with a discharge date, the duration of each hospital stay will be calculated as 
the discharge date minus the admission date (Hospitalization/ER Visit Date on the eCRF) plus 1 day. For hospitalizations with either a partial admission or discharge date, the duration of 
hospital stay will be set to missing. The nonmissing durations of hospital stays will be summed 
within each of the study periods (Baseline, Titration, and Maintenance, respectively). Should distinct records for hospital stays overlap, then the days during the overlap will only be counted 
once. Subjects with no hospital stays within a study period will have duration of 0 days for that 
period. For subjects with hospital stays but no calculable hospital duration, the duration of hospitalization in the respective study period will be missing.
The number of concomitant medical procedures per subject (number of entries in the 
concomitant procedure form) will be summarized continuously and in categories (0, 1, 2, and 3 or more) for the Baseline Period, the Titration Period, and the Maintenance Period. 
The number of healthcare provider consultations per subject will be summarized continuously 
and in categories (0, 1, 2, 3, 4, and 5 or more) for the Baseline Period, the Titration Period, and the Maintenance Period. In addition, the number and percentage of subjects with at least 
1 consultation will be given for general practitioner, specialist physician, nurse, or other by study 
period.
The number of hospital stays per subject will be summarized continuously and in categories (0, 
1, 2, 3, 4, and 5 or more) for the Baseline Period, the Titration Period, and the Maintenance 
Period. The number and percentage of subjects with specific reasons for a hospital stay (epilepsy, lack of efficacy, AE, elective procedure, and other) will also be summarized for these study 
periods. Furthermore, the duration of hospital stays will be summarized in categories (0 days, 1
to 5 days, 6 to 10 days, 11 to 15 days, and >15 days) by study period. Descriptive statistics for the number of ER visits within each study period will be presented. These summaries will be 
repeated by syndrome subgroups (as described in Section 4.8).
9.2 Exploratory  Efficacy Variables
The analysis of the exploratory efficacy variable will be conducted for the FAS.
Days with seizures per 28 days for each seizure type and study period will be calculated as 
described for the generalized seizures in Section 8.1.2 . The days with any generalized seizures REDACTED calccal
d willd will
oceduocedu
e summe summ
TiTiCOPYayays ds 
dydy per peyy
lcullcu
This document e ne 
reperepecannot. FurFur
daydays,s,
numnumbeicacyicacy
thtusedor mor m
umbeumbetopitapita
mosupporten forn for
al stalany ndd
dditionditio
rgmarketing marma
itrationtration
r consuconsu
d 5 od 5 authorizationriodiod
lable hable 
l be mbe m
ures peres pe
arizerizapplication argg
f hospf hosp
aintenaintena
uring tring 
d widwandt DaDa
ge dge danyyywillwilyy
atetextensions visvis
on. Hon. Ho
eral wral wor omo
sitsitvariations om”m”thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 34 of 53per 28 days will only be derived for subjects who completed or discontinued during the 
respective study period. For subjects who discontinued during the Titration period, the missing 
value of the maintenance period will be implemented as described in Section 4.2
Descriptive statistics will be used to summarize the proportion of subjects who have at least a 50 
percent reduction in generalized seizures per 28 days by study period (Titration and Maintenance 
Period) and syndrome subgroup.
Descriptive statistics will also be produced to summarize the proportion of subjects who have 
more than 30% and 50% increase in generalized seizures per 28 days during the study period
(Titration and Maintenance Period) by syndrome subgroup.
Descriptive statistics will be produced to summarize the percent change in days with any 
generalized seizures per 28 days during the study period by syndrome subgroup.
10 PHARMACOKINETICS
10.1 Descriptive statistics of LCM and AED plasma concentrations
The results of LCM plasma concentrations will be described by the method of descriptive 
statistics: n, >=limit of quantification (LOQ), arithmetic mean, SD, median,  geometric mean, 
and geometric CV. Summary statistics will only be calcu lated if at least 2/3 of the data are above 
the lower LOQ. Values <LOQ will be set to LOQ/2 for the determination of summary statistics.
The summary of LCM plasma concentrations will be presented by dose level during the 
Maintenance Period (dose with the longest duration during the Maintenance Period) and visit.The dose levels will be combined as 4-6 mg/kg/da y, 7-8 mg/kg/day, 9-10 mg/kg/day, and 11-12 
mg/kg/day.
Other AED plasma concentrations will only be listed.
10.2 Population pharmacokinetics and exposure response
Population pharmacokinetics and exposure-response modeling are not in the scope of the SAP 
and will be described in separate data analysis plans.
11 OTHER ANALYSES 
Data of Bayley Scales of Infant and Toddler Development®, Third Edition (Bayley-III) and 
Columbia-Suicide Severity Rating Scale will only be listed. The analysis of the Bayley-III scales data will be performed in the follow-up study, SP848.REDACTED Q
nns willsw i l
est durst dur
6 mg6 mCOPY tic ic
calcucalcu
Q/2 foQ/2 f
This document cannot aa-S
will beill bebe yleyey
SuicSuicusedOTHTH
yyScScyyto HEHEsupport n pn 
netics aetics
in sepin seany phaphamarketing g
will onlill onauthorizationfor thefor the
ll be pbe p
ration ation
/kg/dkg/dapplication plasas
byythe mthe yy
ean, SDan, S
lated ated and asmsmany extensions th anh an
p.or variations ve 
iododthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 35 of 5312 REFERENCES
Not applicable.
COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 36 of 5313 APPENDICES
13.1 Significant Adverse Events
Table 13-1: List of other significant AEs
MedDRA Preferred Term
HEPATOTOXICITY RELATED TERMS
Hepatitis toxic
Hepatotoxicity
Drug-induced liver injury
Liver function test abnormal
Alanine aminotransferase increased
Aspartate aminotransferase increased
CARDIAC AND ECG RELATED TERMS
Atrioventricular block complete
Atrioventricular block second degree
Bradyarrhythmia*
Bradycardia*
Cardiac pacemaker insertion
Atrial fibrillation
Atrial flutter
Sinus bradycardia*
Ventricular tachycardia
Ventricular fibrillation
Heart Rate decreased*
Sick sinus syndrome
SUICIDALITY RELATED TERMS
Completed suicide
Depression suicidal
Suicidal behaviour
Suicidal ideation
Suicide attempt
Intentional self-injury
Self injurious behaviourREDACTED D
CT
EDRCOPY Y
OP
This documentSuiciuici
SuSuen
umucannoted sud su
ressionessionno
ddcabe T
suicsuibeused meme
Y REY Redto tosupport rt
ppany ymarketing tin
arkauthorization ati
hor
auapplication tio
plicaand anany anextensions ns
n
exor rorororvariations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 37 of 53Table 13-1: List of other significant AEs
MedDRA Preferred Term
Self-injurious ideation
Intentional overdose
Poisoning deliberate
ADDITIONAL TERMS
Loss of consciousness
Syncope
* All cases with reported reduced heart rate will be reviewed and only cases with marked bradycardia (marked 
reduction in heart rate) with HR <45 bpm will be listed as ‘Other Significant AEs’.
13.2 Marked abnormality criteria for laboratory data
13.2.1 Marked abnormality criteria for hematology data
Table 13 ‒2: Hematology abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality 
criteria 
(conventional 
unit)Unit 
(standard)Abnormality 
criteria 
(standard 
unit)
Hematocrit <2y % ≤27
>45% ≤27
>45
2y - <17y % ≤29
>47% ≤29
>47
≥17y % ≤85% of LLN
≥115% of ULN% ≤85% of LLN
≥115% of ULN
Hemoglobin <2y g/dL ≤9.0
>15.0g/L ≤90
>150
2y - <17y g/dL ≤9.5
>16.0g/L ≤95
>160
≥17y g/dL ≤85% of LLN
≥115% of ULNg/L ≤85% of LLN
≥115% of ULN
WBC/ 
LeukocytesAll 109/L ≤3.0
≥16.0G/L ≤3.0
≥16.0
Lymphocytes 
Absolute<2y 109/L <1.0
>9.8G/L <1.0
>9.8
2y - <6y 109/L <0.7
>6.9G/L <0.7
>6.9REDACTED D
AC
RCOPY AbnorAbnor
critcrit
(Y
This documentWBCWBC
LeuLeu
umuuucaC/C/cannot cabe beused 2y 2y d
usto tsupport poany %%anmarketing ting
mauthorization rm
eria eria 
conveonve
unitunit
hohhohohoapplication ydd
malitymalitypland datat
dataataany tataextensions ns
ns dycarddycaror rorvariations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 38 of 53Table 13 ‒2: Hematology abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality 
criteria 
(conventional 
unit)Unit 
(standard)Abnormality 
criteria 
(standard 
unit)
≥6y 109/L <0.6
>5.0G/L <0.6
>5.0
Basophils >1m % ≥5.0 % ≥5.0
Basophils 
Absolute>1m 109/L ≥0.4 G/L ≥0.4
Eosinophils >1m % ≥10 % ≥10
Eosinophils 
Absolute>1m 109/L ≥1.0 G/L ≥1.0
Monocytes >1m % ≥20.0 % ≥20.0
Monocytes 
Absolute>1m 109/L ≥2.0 G/L ≥2.0
Neutrophils 
Absolute>1m 109/L <1.5 G/L <1.5
Platelets >1m 109/L ≤100
≥600G/L ≤100
≥600
RBC/ 
Erythrocytes<2y 1012/L <3.0 T/L <3.0
≥2y 1012/L <3.5 T/L <3.5
LLN=lower limit of normal, m=month, RBC=red blood cells, ULN=upper limit of normal, WBC=white blood cells, 
y=year. 
A month is defined as 30 days; a year is defined as 365.25 days.
13.2.2 Marked abnormality criteria for chemistry data
Table 13 ‒3: Chemistry abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality 
criteria 
(conventional unit)Unit 
(standard)Abnormality 
criteria 
(standard unit)
AST (SGOT) All U/L ≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULNU/L ≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULN
ALT (SGPT) All U/L ≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULNU/L ≥3.0 x ULN
≥5.0 x ULN
≥10.0 x ULNRED22/L/LEDACTED DEDDDD
EDCOPY <1.5<1.5PY
This documentAST AST t
umcannot cbe usedChemhem
Asseusto mmsupport a yeara yea
ed d abnabany h, h, RBRmarketing 00122/L/Lrk
mBCBauthorization ≤10≤10za
ho
aapplication %%
iGGiiioati
ppand anany yextensions ≥0.4≥0.4s
enenenenen
eor ovariations nnnon
vathereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 39 of 53Table 13 ‒3: Chemistry abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality 
criteria 
(conventional 
unit)Unit 
(standard)Abnormality 
criteria 
(standard 
unit)
Alkaline Phosphatase<4y U/L ≥690 U/L ≥690
4y - <10y U/L ≥834 U/L ≥834
10y - <17y U/L ≥1761 U/L ≥1761
≥17y U/L ≥3.0 x ULN U/L ≥3.0 x ULN
GGT <6m U/L ≥522 U/L ≥522
6m - <1y U/L ≥279 U/L ≥279
1y - <13y U/L ≥66 U/L ≥66
13y - <17y U/L ≥126 U/L ≥126
≥17y U/L ≥3.0 x ULN U/L ≥3.0 x ULN
Total Bilirubin >1m mg/dL ≥2.0 umol/L ≥34.208
Total Protein 2m-<1y g/dL <3.0
>11.9g/L <30
>119
1y - <17y g/dL <4.3
>12.0g/L <43
>120
≥17y g/dL <4.3
>13.0g/L <43
>130
Albumin <1y g/dL <1.6
>7.2g/L <16
>72
≥1y - <17y g/dL <2.4
>8.4g/L <24
>84
≥17y g/dL <2.6 g/L <26
BUN <1y mg/dL ≥24 mmol/L ≥8.568
1y - <17y mg/dL ≥36 mmol/L ≥12.852
≥17y mg/dL ≥40 mmol/L ≥14.28
Creatinine 1y - <10y mg/dL >1.2 umol/L >106.8
10y - <16y mg/dL >1.8 umol/L >159.12
≥16y mg/dL ≥2.0 umol/L ≥176.8REDACTED D
AC
RCOPYxx
≥2.0≥2.0PY 
<3<3CO
This document CreaCreat
mmmumcannot t
nnbe bused ≥17≥17d
usuusususto tsupport <17y17ypoany g/dg/yanmarketing Ltin
mauthorization 3.0.0
>11>11on
hohhohohoapplication U/LU/n
atiNNatatatat
ppand /LLdaany yextensions ≥17611761
≥3≥io
enteeeeor ovariations nnnon
vathereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 40 of 53Table 13 ‒3: Chemistry abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality 
criteria 
(conventional 
unit)Unit 
(standard)Abnormality 
criteria 
(standard 
unit)
Bicarbonate >1m - <17y mEq/L <15
>38mmol/L <15
>38
≥17y mEq/L <18
>38mmol/L <18
>38
Calcium<1y mg/dL <6.9
>12.2mmol/L <1.725
>3.05
1y - <17y mg/dL <7.4
>11.7mmol/L <1.85
>2.925
≥17y mg/dL ≤7.6
≥11.0mmol/L ≤1.9
≥2.75
Chloride >1m mEq/L ≤90
≥112mmol/L ≤90
≥112
Phosphorous <1y mg/dL <1.8
>8.2mmol/L <0.5814
>2.6486
1y - <17y mg/dL <1.8
>7.4mmol/L <0.5814
>2.3902
≥17y mg/dL ≤2.0
≥6.0mmol/L ≤0.646
≥1.938
Potassium <1y mEq/L ≤3.0
≥6.5mmol/L ≤3.0
≥6.5
≥1y mEq/L ≤3.0
≥6.0mmol/L ≤3.0
≥6.0
Sodium >1m mEq/L <127
>151mmol/L <127
>151
Glucose >1m - <17y mg/dL <50
≥180mmol/L <2.775
≥9.99
≥17y mg/dL <50
≥200mmol/L <2.775
≥11.1
Total 
Cholesterol≥1y mg/dL >250 mmol/L >6.475
Triglycerides <1y mg/dL >750 mmol/L >8.475
≥1y mg/dL >300 mmol/L >3.39D
LLACCOPY 00
≥112≥112
C
This document t
umcannot et
cbe bused >1m>1md
usto support ppany mmyanmarketig/dLdLting etiauthorization <1.81.8
>8.>8.ion
hothhhhapplication mmmm
atilicand moanany Lextensions >388
<1<1io
en
eor variations nnnon
vathereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 41 of 53Table 13 ‒3: Chemistry abnormality criteria
Parameter Age Range Unit 
(conventional)Abnormality 
criteria 
(conventional 
unit)Unit 
(standard)Abnormality 
criteria 
(standard 
unit)
Uric Acid <1y mg/dL >7.7 umol/L >457.996
1y - <13y mg/dL >6.5 umol/L >386.62
13y - <17y mg/dL >8.6 umol/L >511.528
≥17y mg/dL >9.5 umol/L >565.06
Thyroxine (T4) <1y ug/dL ≤4.3
≥18.4nmol/L ≤55.3453
≥236.8264
≥1y ug/dL ≤3.8
≥13.5nmol/L ≤48.9098
≥173.7585
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; dL=deciliter; 
GGT=gamma-glutamyltransferase; HDL=high density lipoprotein; LDL=low density lipoprotein; L=liter; 
m=month (a month is defined as 30 days); mg=milligram; mmol=millimoles; μg=microgram; U=unit; ULN=upper 
limit of normal; y=years (a year is defined as 365.25 days)
REDACTED COPY oll
This document cannot be used to support any marketing authorization applicationn od uread urea
=low=low  dedww
limoles;molesand /L/L
aanyLny nyextensions1
>565>565ns 
≤≤nnnsenor.528528variations nnnon
iat
vthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 42 of 5314 AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN 
(SAP)
14.1 Amendment 1
Rationale for the amendment
The SAP has been amended to implement any changes to the planned analyses made during the 
course of the study since the approval of the previous version of the SAP and to incorporate any clarification to the text.
Modifications and changes
Global changes
The following global changes were applied to SAP version 1.0
!Clarification that ‘Last Visit’ cannot use the baseline assessment
!Specification that for ECGs, average of all interpretable readings at the visit will be used 
in summaries
!Change in which questions contribute to which scale in the CBCL/6-18
!Addition of Inhibitory self-control scale to BRIEF-P scoring table
!Addition of question 28 to Pan/organize scale of BRIEF scoring table
!Addition of Psychological Health Summary Score in pediatric quality of life inventory
!LCM plasma concentrations are the only concentrations to be summarized. The 
presentation of specific dose levels has been added. Other AED concentrations are now 
only listed
!Changes in the presentation of the Nonserious TEAEs
!Presentation of compliance by visit has been removed
!Addition of two new shift tables, one for single neurological parameters and one for 
physical examinations
!Addition of summary of proportion of responders greater than 50 percent reduction in 
generalize seizures per 28 days during the study period by syndrome subgroup
!Change of the name of phosphorus to phosphate, total serum protein to total protein and
blood urea nitrogen to urea nitrogen
!Typographical corrections
!Dating and version control
!Addition of exploratory safety variables and its analyses
!Addition of exploratory efficacy variables and its analyses
!Change of some of the section numbers and nameREDACTED anize snize s
th Sumth Sum
are tare tCOPYich sch sc
o BRo BR
This document !!cannotChanChan
blblbeeralralused on of n of 
lizliztoaminamisupportmpliamplia
wo newo new
naanyationationmarketingthe onthe o
evels hevelsauthorizationRIEFRIEF
scale ocale o
mmarmmarapplicationreadineadin
ale in tle inand entntany extensions or variations the he 
te ane anythereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 43 of 53Specific Changes
Change #1
Section 3.2.4 Last Visit
The Last Visit for all assessments in SP0966 is the last non-missing assessment during the 
Treatment Period. All scheduled and unscheduled assessments within this time period will be 
considered. Last Visit will be determined separately for each study procedure where Last Visit is 
mentioned within this document.
Has been changed to:
The Last Visit for all assessments in SP0966 is the last non-missing assessment during the 
Treatment Period. This cannot be the same assessment as the baseline assessment. All scheduled and unscheduled assessments within this time period will be considered. Last Visit will be 
determined separately for each study procedure where Last Visit is mentioned within this 
document.
Change #2
Section 8.5.2 Electrocardiograms
The average of all interpretable readings for a measurement will be used for summaries. 
Observed results and changes from Baseline in ECG results will be summarized for all visits and 
the Last Visit.
The number and percentage of subjects with no abnormality, an abnormal but not clinically 
significant finding, and a clinically significant finding, will be summarized by visit.
Has been changed to:
For ECGs, Baseline will be defined as the average of all pre-dose interpretable readings. For all 
post-Baseline visits, the average of all interpretable readings at the specified visit will be used for 
summaries. 
Observed results and changes from Baseline in ECG results will be summarized for all visits and 
the Last Visit.
The number and percentage of subjects with no abnormality, an abnormal but not clinically
significant finding, and a clinically significant finding, will be summarized by visit, including last visit.REDACTED h no ah no a
ificantficanCOPYremrem
CG resG res
This document cannot be used g, ag, toce
andandsupportges fes f
entagentagany fromfromarketing as the as the a
f all intall inauthorization sul
abnormbnorm
t findifindapplication nt will bt will
ults wlts wand anyned nedextensions ring thring th
nt. t. AlAl
t ViVisitsi
dwdwor variations t is is thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 44 of 53Change #3
Table 8-2 CBCL/6-18
Syndrome scale Questions
Aggressive behavior 3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 94, 95, 97, 104
Anxious/depressed 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
Attention problems 1, 8, 10, 13, 17, 41, 61, 80
Rule-breaking behavior 26, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 101, 106
Social problems 11, 12, 25, 27, 34, 36, 38, 48, 62, 64, 79
Somatic complaints 47, 49, 51, 54, 56a, 56b, 56c, 56d, 56e, 56, 56g
Thought problems 9, 18, 40, 46, 58, 59, 60, 66, 70, 76, 83, 84, 85, 92, 100
Withdrawn/depressed 42, 65, 69, 75, 102, 103, 111
Has been changed to:
Syndrome scale Questions
Aggressive behavior 3, 16, 19, 20, 21, 22, 23, 37, 57, 68, 86, 87, 88, 89, 94, 95, 97, 104
Anxious/depressed 14, 29, 30, 31, 32, 33, 35, 45, 50, 52, 71, 91, 112
Attention problems 1, 4, 8, 10, 13, 17, 41, 61, 78, 80
Rule-breaking behavior 2, 26, 28, 39, 43, 63, 67, 72, 73, 81, 82, 90, 96, 99, 101, 105, 106
Social problems 11, 12, 25, 27, 34, 36, 38, 48, 62, 64, 79
Somatic complaints 47, 49, 51, 54, 56a, 56b, 56c, 56d, 56e, 56f, 56g
Thought problems 9, 18, 40, 46, 58, 59, 60, 66, 70, 76, 83, 84, 85, 92, 100
Withdrawn/depressed 5, 42, 65, 69, 75, 102, 103, 1112, 332, 3
13, 173, 17TE
28, 3928, 39DAC
22RECOPY23, 3723, PY 
33CO
This document cannot be used to supporttt 
pprtany9, 189, 1a
5amarketing , 4
25, 27, 5, 27ng
49, 5149, 5ke
mauthorization 7, 5,
35, 435, 4on
7, 41, 6, 41, 6iz
43, 643, 6uthapplication at
57, 657, ppand anany92, 92,
anextensions ns
ns
11exor variations onat
vthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 45 of 53Change #4
Table 8-3 BRIEF-P questionnaire scoring
Scale/Index Questions
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 60, 62
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46
BRI All from {Inhibit, Shift, and Emotional Control}
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 59, 61, 63
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49
MI All from {Working Memory and Plan/Organize}
GEC Score 1-63
BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite
Has been changed to:
Scale/Index Questions
Inhibit 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 52, 54, 56, 58, 60, 62
Shift 5,10, 15, 20, 25, 30, 35, 40, 45, 50
Emotional Control 1, 6, 11, 16, 21, 26, 31, 36, 41, 46
Inhibitory self-control All from {Inhibit and Emotional Control}
Flexibility All from {Shift, and Emotional Control}
Working Memory 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 51, 53, 55, 57, 59, 61, 63
Plan/Organize 4, 9, 14, 19, 24, 29, 34, 39, 44, 49
MI All from {Working Memory and Plan/Organize}
GEC Score 1-63
MI=Metacognition Index, GEC=Global Executive CompositeREDACTED 23, 2823, 28ED
, 20, 2, 20, 2AC
11, 111, 1RECOPY CO
This document cannot benitionnitioused d
uto support rtpo
suanyAll fAll 
22anyamarketing 16, 21,6, 21g
from {Irom ket
frofrmaauthorization n
8, 33, 333, 3za
25, 30,5, 30ho
aapplication tio xecutivecuti
aandOrgarga
anany anianextensionsns 
9, 61, , 61ns
exor variations onat
vthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 46 of 53Change #5
Table 8-4 BRIEF questionnaire scoring
Scale/Index Questions
BRI All from {Inhibit, Shift, and Emotional Control}
Initiate 3, 10, 16, 47, 48, 61, 66, 71
Working Memory 2, 9, 17, 19, 24, 27, 32, 33, 37, 57
Plan/Organize 11, 15, 18, 22, 35, 36, 40, 46, 51, 53, 58
Organization of Materials 4, 29, 67, 68, 69, 72
Monitor 14, 21, 31, 34, 42, 52, 60, 63
MI All from {Initiate, Working Memory, Plan/Organize, Organization 
of Materials, and Monitor}
GEC Score 1-72
BRI=Behavioral Regulation Index, MI=Metacognition Index, GEC=Global Executive Composite
Has been changed to:
Scale/Index Questions
BRI All from {Inhibit, Shift, and Emotional Control}
Initiate 3, 10, 16, 47, 48, 61, 66, 71
Working Memory 2, 9, 17, 19, 24, 27, 32, 33, 37, 57
Plan/Organize 11, 15, 18, 22, 28, 35, 36, 40, 46, 51, 53, 58
Organization of Materials 4, 29, 67, 68, 69, 72
Monitor 14, 21, 31, 34, 42, 52, 60, 63
MI All from {Initiate, Working Memory, Plan/Organize, Organization 
of Materials, and Monitor}
GEC Score 1-72
MI=Metacognition Index, GEC=Global Executive CompositeREDACTED hibit, Shibit, SD
47, 4847, 4CT
17, 1917, 19EDRCOPY OPC
This document cannot be used edon Indon Indto osupport rtortrttrt
sany 14, 14, nyamarketing 9, 24,, 24
5, 18, 2218, 2tin
29, 6729, 6arauthorization Shift, hift, tio
8, 61, , 61, or
22auapplication on ecutive cutive
apand ndanyOrgaOrgaextensions ns
ns
anexor variations onat
vthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 47 of 53Change #6
Section 9.4 Pediatric Quality of Life Inventory
Each scale score is then calculated as the mean of the corresponding nonmissing items if 50% or 
more of the items are nonmissing. The same algorithm will be used to calculate an overall total scale score (all scales) for each subject.
Has been changed to:
Each scale score is then calculated as the mean of the corresponding nonmissing items if 50% or 
more of the items are nonmissing. The same algorithm will be used to calculate an overall Total 
Scale Score (all scales) and the Psychosocial Health Summary Score (a combination of the 
emotional, social and school functioning questions) for each subject.
Change #7
Section 10.1 Descriptive statistics of LCM and AED plasma concentrations 
The results of LCM and other AEDs plasma concentrations will be described by the method of 
descriptive statistics: n, >=limit of quantification (LOQ), arithmetic mean, SD, median, range, 
geometric mean, and geometric CV. Summary statistics will only be calculated if at least 2/3 of 
the data are above the lower LOQ. Values <LOQ will be set to LOQ/2 for the determination of summary statistics.
The summary of LCM and other AEDs plasma concentration will be presented by dose level 
during the Maintenance Period (dose with the longest duration during the Maintenance Period) and visit.
Has been changed to:
The results of LCM plasma concentrations will be described by the method of descriptive 
statistics: n, >=limit of quantification (LOQ), arithmetic mean, SD, median, geometric mean, and 
geometric CV. Summary statistics will only be calculated if at least 2/3 of the data are above the 
lower LOQ. Values <LOQ will be set to LOQ/2 for the determination of summary statistics.
The summary of LCM plasma concentrations will be presented by dose level during the 
Maintenance Period (dose with the longest duration during the Maintenance Period) and visit.
The dose levels will be combined as 4-6 mg/kg/da y, 7-8 mg/kg/day, 9-10 mg/kg/day, and 11-12 
mg/kg/day.
Other AED plasma concentrations will only be listed.
Change #8
Section 8.2.2 Adverse Events 
The following summaries of AEs will be provided by primary SOC and PT:
!TEAEs
!TEAEs during the Titration Period
!TEAEs during the Maintenance Period
!TEAEs by syndrome subgroups (as described in Section 4.8)REDACTEDco
he longhe lon
atiatCOPY b
onceonce
This documentThe The 
!!cannot #8#8
ion 8on 8
ffbe p
88used lasmaasmto bsupportasma csma 
osesewiw
be comec oanyl be sl be marketing tions wons w
on (LOn (LO
swillwilauthorizationentratientrat
gest dgest dapplicationtic mc m
nlylybebeyy
t to Lto LOOandescribescri
memeanyationation
bextensionsn of thof thorall all TTvariations 0% o0% o
Tthereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 48 of 53!TEAEs including subject numbers
!Serious TEAEs
!Serious TEAEs including subject numbers
!TEAEs leading to discontinuation
!TEAEs leading to discontinuation including subject numbers
!TEAEs by maximum intensity
!Nonserious TEAEs occurring in > 5% of subjects
!Other significant TEAEs
Has been changed to:
The following summaries of AEs will be provided by primary SOC and PT:
!TEAEs
!TEAEs during the Titration Period
!TEAEs during the Maintenance Period
!TEAEs by syndrome subgroups (as described in Section 4.8)
!TEAEs including subject numbers
!Serious TEAEs
!Serious TEAEs including subject numbers
!TEAEs leading to discontinuation
!TEAEs leading to discontinuation including subject numbers
!TEAEs by maximum intensity
!Nonserious TEAEs 
!Nonserious TEAEs occurring in > 5% of subjects
!Other significant TEAEs
Change #9
Section 8.2.2 Adverse Events 
The following summaries by primary SOC and PT will be presented overall only (ie, not by age 
group).
!Nonserious TEAEs 
!TEAEs by relationship to LCM
!Serious TEAEs by relationship to LCM
!Nonserious TEAEs by relationship to LCMREDACTED numbenumbe
ononCOPYn Sectn Sec
This documentThe he 
grougrocannot #9#
on 8.2n 8.2
fofobe 99used anantont Tnt Tsupport Es occuoccu
Eany sitysitymarketing iononincinauthorization ersrsapplication ionon4.84and any T:T:extensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 49 of 53!Fatal TEAEs by relationship to LCM
!Nonserious TEAEs occurring in at least 5% of subjects by relationship
Has been changed to:
The following summaries by primary SOC and PT will be presented overall only (ie, not by age 
group).
!TEAEs by relationship to LCM
!Serious TEAEs by relationship to LCM
!Nonserious TEAEs by relationship to LCM
!Fatal TEAEs by relationship to LCM
!Nonserious TEAEs occurring in at least 5% of subjects by relationship
Change #10
Section 7.2 Presentation of compliance
Compliance will be summarized separately for the Treatment Period, the Titration Period, the 
Maintenance Period and each visit for the SS.  It will be presented with descriptive statistics and 
additionally categorized as <75%, ≥75% to ≤125%, and >125% 
Has been changed to:
Compliance will be summarized separately for the Treatment Period, the Titration Period and the 
Maintenance Period. It will be presented with descriptive statistics and additionally categorized 
as <75%, ≥75% to ≤125%, and >125% 
Change #11
Section 8.5.3 Physical and Neurological Examinations
Summaries of shift from Baseline to Visit 9/ET will be provided based on categories normal, 
abnormal, not clinically significant, and abnormal, clinically significant for each of the single 
neurological examinations. Examinations at other visits will only be listed. 
Has been changed to:
Summaries of shift from Baseline to Visit 9/ET will be provided based on categories normal, 
abnormal, not clinically significant, and abnormal, clinically significant for each of the single 
neurological examinations. Summaries of shift from Baseline normal to any post-baseline abnormal, clinically significant category for each of the neurological examinations will also be 
provided. For physical examination summaries of shift from Baseline normal to any post-
baseline abnormal, clinically significant category will be presented. REDACTEDIt wIt w
≤≤125125
parateparatCOPY he Tree Tre
wii
This document eurur
abnoabno
prprcannotaries ries 
rmal, rmal,
rolorolobe hanhanusedaminmin
angengeto callcallysupportnd Ned Ne
om Bam Ba
llysyany marketingtelyelyfofoyy
nted wited w
25% 25% authorizationeatmatm
ill be pl be 
5%, an%, anapplication menmenand shihiany ippextensions or variations ethereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 50 of 53Change #12
Section 2.2.1.4 Exploratory safety variables 
Has been added:
Decrease in generalized spike-wave discha rges on 24-hour ambulatory  EEG by syndrome 
subgroups.
Change #13 
Section 8.4 Clinical laboratory evaluations
Chemistry: calcium, serum electrolytes (sodium, potassium, chloride, bicarbonate), total serum 
protein, albumin, phosphorus, glucose, uric acid, alkaline phosphatase, blood urea nitrogen, 
creatinine, aspartate aminotransferase, alanine aminotransferase, gamma glutamyltransferase, total bilirubin, cholesterol, triglycerides
Has been changed to:
Chemistry: calcium, serum electrolytes (sodium, potassium, chloride, bicarbonate), total protein, 
albumin, phosphate, glucose, uric acid, alkaline phosphatase, urea nitrogen, creatinine, aspartate 
aminotransferase, alanine aminotransferase, gamma glutamyltransferase, total bilirubin, 
cholesterol, triglycerides
Change #14
Section 8.3 Exploratory safety variables 
Has been added as a new section
A frequency table will be presented for the number of subjects with a decrease of at least 30% 
and a decrease of at least 50% in generalized spike-wave discharges on 24-hour EEG at Visit 6 
compared to Baseline by syndrome subgroups
Change #15
Section 2.2.2 Preliminary efficacy variables 
Has been changed to:
Section 2.2.2 Efficacy variables 
Change #16
Section 2.2.2 Preliminary efficacy variables Has been changed to:
Section 2.2.2.1 Preliminary efficacy variables 
Change #17
New section 2.2.2.2 exploratory efficacy variables has been added 
Change #18
Section 9 Analyses of Preliminary Efficacy VariablesHas been changed to:REDACTED fofor ther the
neraneraCOPY 
This document ChaChacannoteen chen ch
tion ion be2.2 P2.2 Pused PrPrto acyacysupport effeff
varvaany ficacficamarketing e nun
alized alized 
subgroubgrauthorization numumapplicationea nitrea nit
transfetransfand e, bic, bicany extensionstotal otal 
a nitronitro
mymyltraltraor variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 51 of 53Section 9 Analyses of Efficacy Variables
Change #19
Section 9.1 Seizure days
Has been changed to:
Section 9.1 Preliminary Efficacy Variables
Change #20
Section 9.1 Seizure daysHas been changed to:
Section 9.1.1 Seizure days
Change #21
Section 9.2 Clinical Global Impression of Change
Has been changed to:
Section 9.1.2 Clinical global impression of change
Change #22
Section 9.3 Caregivers Global Impression of Change
Has been changed to:
Section 9.1.3 Caregivers global Impression of change
Change #23
Section 9.4 Pediatric Quality of Life InventoryHas been changed to:
Section 9.1.4 Pediatric quality of life inventory
Change #24
Section 9.5 Health care resource use
Has been changed to:
Section 9.1.5 Health care resource use
Change #25
New section 9.2 Exploratory Efficacy Variables
Has been added:
The analysis of the exploratory efficacy variable will be conducted for the FAS.
Days with seizures per 28 days for each seizure type and study period will be calculated as 
described for the generalized seizures in Section 8.1.2 . The days with any generalized seizures 
per 28 days will only be derived for subjects who completed or discontinued during the REDACTED ion ofon oCOPY Changhang
This documentHas Has 
TTcannote #25#25
w sectsectbe 5 
55usedged ted t
HeaHeato totosupport are rere rany yof lifof liymarketing fe Invee Invauthorization gege
f chanchanapplication and any extensions or variations thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 52 of 53respective study period. For subjects who discontinued during the Titration period, the missing 
value of the maintenance period will be implemented as described in Section 4.2
Descriptive statistics will be used to summarize the proportion of subjects who have at least a 50 
percent reduction in generalized seizures per 28 days by study period (Titration and Maintenance Period) and syndrome subgroup.
Descriptive statistics will also be produced to summarize the proportion of subjects who have 
more than 30% and 50% increase in generalized seizures per 28 days during the study period (Titration and Maintenance Period) by syndrome.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations d thereof. 
UCB 06 March 2018
Statistical Analysis Plan Lacosamide SP0966
Confidential Page 53 of 53STATISTICAL ANALYSIS PLAN SIGNATURE PAGE
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analysis Plan (SAP) or amended SAP is released for execution.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
ELECTRONIC SIGNATURES
Signed by Meaning of Signature Server Approval Date 
(dd-mon-yyyy
(HH:mm))636$3$PHQGPHQW
&OLQLFDO$SSURYDO 0DU*07
&OLQLFDO$SSURYDO 0DU*07
COPY DOO
This document cannot be used to support any marketing authorization applicationnn aannd anayany erveayextensions or variations thereof. 